Document:

<PAGE>   1
                                                                    EXHIBIT 10.7

                                                            REVOLVING CREDIT
                                                       LOAN & SECURITY AGREEMENT
                                                        (ACCOUNTS AND INVENTORY)

--------------------------------------------------------------------------------
OBLIGOR #                  NOTE #                AGREEMENT DATE
3954357024                                       December 20, 1999
--------------------------------------------------------------------------------
CREDIT LIMIT                   INTEREST RATE               OFFICER NO./INITIALS
$5,000,000.00                  Base Rate+ 0.000%           48234, Brock Mullins
--------------------------------------------------------------------------------

         THIS AGREEMENT is entered into on December 20, 1999, between Comerica
Bank-California ("Bank") as secured party, whose Headquarter Office is 333
West Santa Clara Street, San Jose, CA and JMAR Technologies, Inc. ("Borrower"),
a Corporation whose sole place of business (if it has only one), chief
executive office (If it has more than one place of business) or residence (if
an individual) is located at 3956 Sorrento Valley Blvd., San Diego, CA. The
parties agree as follows:

1.   DEFINITIONS

          1.1  "Agreement" as used in this Agreement means and includes this
     Revolving Credit Loan & Security Agreement (Accounts and Inventory), any
     concurrent or subsequent rider to this Revolving Credit Loan & Security
     Agreement (Accounts and Inventory) and any extensions, supplements,
     amendments or modifications to this Revolving Credit Loan & Security
     Agreement (Accounts and Inventory) and to any such rider.

          1.2  "Bank Expenses" as used in this Agreement means and includes:
     all costs or expenses required to be paid by Borrower under this Agreement
     which are paid or advanced by Bank; taxes and insurance premiums of every
     nature and kind of Borrower paid by Bank; filing, recording, publication
     and search fees, appraiser fees, auditor fees and costs, and title
     insurance premiums paid or incurred by Bank in connection with Bank's
     transactions with Borrower; costs and expenses incurred by Bank in
     collecting the Receivables (with or without suit) to correct any default
     or enforce any provision of this Agreement, or in gaining possession of,
     maintaining, handling, preserving, storing, shipping, selling, disposing
     of, preparing for sale and/or advertising to sell the Collateral, whether
     or not a sale is consummated; costs and expenses of suit incurred by Bank
     in enforcing or defending this Agreement or any portion hereof, including,
     but not limited to, expenses incurred by Bank in attempting to obtain
     relief from any stay, restraining order, injunction or similar process
     which prohibits Bank from exercising any of its rights or remedies; and
     attorneys' fees and expenses incurred by Bank in advising, structuring,
     drafting, reviewing, amending, terminating, enforcing, defending or
     concerning this Agreement, or any portion hereof or any agreement related
     hereto, whether or not suit is brought. Bank Expenses shall include Bank's
     in-house legal charges at reasonable rates.

          1.3  "Base Rate" as used in this Agreement means that variable rate
     of interest so announced by Bank at its headquarters office in San Jose,
     California as its "Base Rate" from time to time and which serves as the
     basis upon which effective rates of interest are calculated for those
     loans making reference thereto. See Addendum B attached.

          1.4  "Borrower's Books" as used in this Agreement means and includes
     all of the Borrower's books and records including but not limited to:
     minute books; ledgers; records indicating, summarizing or evidencing
     Borrower's assets, liabilities, Receivables, business operations or
     financial condition, and all information relating thereto, computer
     programs; computer disk or tape files; computer printouts; computer runs;
     and other computer prepared information and equipment of any kind.

          1.5  "Borrowing Base" as used in this Agreement means the sum of:
     (1) Eighty percent (80.000%) of the net amount of Eligible Accounts after
     deducting therefrom all payments, adjustments and credits applicable
     thereto ("Accounts Receivable Borrowing Base"); and (2) the amount, if
     any, of the advances against inventory agreed to be made pursuant to any
     Inventory Rider ("Inventory Borrowing Base"), or other rider, amendment or
     modification to this Agreement, that may now or hereafter be entered into
     by Bank and Borrower. See Addendum A attached.

          1.6  "Cash Flow" as used in this Agreement means, for any applicable
     period of determination, the Net Income (after deduction for income taxes
     and other taxes of such person determined by reference to income or
     profits of such person) for such period, plus, to the extent deducted in
     computation of such Net Income, the amount of depreciation and
     amortization expense and the amount of deferred tax liability during such
     period, all as determined in accordance with GAAP. The applicable period
     of determination will be N/A, beginning with the period from _____________
     __________ to __________________________.

          1.7  "Collateral" as used in this Agreement means and includes each
     and all of the following: the Receivables; the Intangibles; the negotiable
     collateral, the Inventory; all money, deposit accounts and all other
     assets of Borrower in which Bank receives a security interest or which
     hereafter come into the possession, custody or control of Bank; and
     the proceeds of any of the foregoing, including, but not limited to,
     proceeds of insurance covering the collateral and any and all Receivables,
     Intangibles, negotiable collateral, Inventory, equipment, money, deposit
     accounts or other tangible and intangible property of borrower resulting
     from the sale or other disposition of the collateral, and the proceeds
     thereof. Notwithstanding anything to the contrary contained herein,
     collateral shall not include any waste or other materials which have been
     or may be designated as toxic or hazardous by Bank.

          1.8  "Credit" as used in this Agreement means all Obligations, except
     those obligations arising pursuant to any other separate contract,
     instrument, note, or other separate agreement which, by its terms,
     provides for a specified interest rate and term.

                                       1.
<PAGE>   2
                                                            REVOLVING CREDIT
                                                       LOAN & SECURITY AGREEMENT
                                                         (Accounts & Inventory)

     1.9  "Current Assets" as used in this Agreement means, as of any
applicable date of determination, all cash, non-affiliated customer
receivables, United States government securities, claims against the United
States government, and inventories.

     1.10 "Current Liabilities" as used in this Agreement means, as of any
applicable date of determination, (i) all liabilities of a person that should
be classified as current in accordance with GAAP, including without limitation
any portion of the principal of the Indebtedness classified as current, plus
(ii) to the extent not otherwise included, all liabilities of the Borrower to
any of its affiliates whether or not classified as current in accordance with
GAAP.

     1.11 "Daily Balance" as used in this Agreement means the amount determined
by taking the amount of the Credit owed at the beginning of a given day, adding
any new Credit advanced or incurred on such date, and subtracting any payments
or collections which are deemed to be paid and are applied by Bank in reduction
of the Credit on that date under the provisions of this Agreement.

     1.12 "Eligible Accounts" as used in this Agreement means and includes those
accounts of Borrower which are due and payable within Thirty (30) days, or less,
from the date of invoice, have been validly assigned to Bank and strictly comply
with all of Borrower's warranties and representations to Bank; but Eligible
Accounts shall not include the following: (a) accounts with respect to which the
account debtor is an officer, employee, partner, joint venturer or agent of
Borrower; (b) accounts with respect to which goods are placed on consignment,
guaranteed sale or other terms by reason of which the payment by the account
debtor may be conditional; (c) accounts with respect to which the account debtor
is not a resident of the United States; (d) accounts with respect to which the
account debtor is the United States or any department, agency or instrumentality
of the United States; (e) accounts with respect to which the account debtor is
any State of the United States or any city, county, town, municipality or
division thereof; (f) accounts with respect to which the account debtor is a
subsidiary of, related to, affiliated or has common shareholders, officers or
directors with Borrower; (g) accounts with respect to which Borrower is or may
become liable to the account debtor for goods sold or services rendered by the
account debtor to Borrower; (h) accounts not paid by an account debtor within
ninety (90) days from the date of the invoice; (i) accounts with respect to
which account debtors dispute liability or make any claim, or have any defense,
crossclaim, counterclaim, or offset; (j) accounts with respect to which any
Insolvency Proceeding is filed by or against the account debtor, or if account
debtor becomes insolvent, fails or goes out of business; and (k) accounts owed
by any single account debtor which exceed twenty percent (20%) of all of the
Eligible Accounts; and (l) accounts with a particular account debtor on which
over twenty-five percent (25%) of the aggregate amount owing is greater than
ninety (90) days from the date of the invoice. See Addendum A attached.

     1.13 "Event of Default" as used in this Agreement means those events
described in Section 7 contained herein below.

     1.14 "Fixed Charges" as used in this Agreement means and includes, for any
applicable period of determination, the sum, without duplication, of (a) all
interest paid or payable during such period by a person on debt of such person,
plus (b) all payments of principal or other sums paid or payable during such
period by such person with respect to debt of such person having a final
maturity more than one year from the date of creation of such debt, plus (c) all
debt discount and expense amortized or required to be amortized during such
period by such person, plus (d) the maximum amount of all rents and other
payments paid or required to be paid by such person during such period under any
lease or other contract or arrangement providing for use of real or personal
property in respect of which such person is obligated as a lessee, use or
obligor, plus (e) all dividends and other distributions paid or payable by such
person or otherwise accumulating during such period on any capital stock of such
person, plus (f) all loans or other advances made by such person during such
period to any Affiliate of such person. The applicable period of determination
will be N/A, beginning with the period from ____________________ to
___________________.

     1.15 "GAAP" as used in this Agreement means as of any applicable period,
generally accepted accounting principles in effect during such period.

     1.16 "Insolvency Proceeding" as used in this Agreement means and includes
any proceeding or case commenced by or against the Borrower, or any guarantor
of Borrower's Obligations, or any of borrower's account debtors, under any
provisions of the Bankruptcy Code, as amended, or any other bankruptcy or
insolvency law, including but not limited to assignments for the benefit of
creditors, formal or informal moratoriums, composition or extensions with
some or all creditors, any proceeding seeking a reorganization, arrangement or
any other relief under the Bankruptcy code, as amended, or any other bankruptcy
or insolvency law.

     1.17 "Intangibles" as used in this Agreement means and includes all of
Borrower's present and future general Intangibles and other personal property
(including, without limitation, any and all rights in any legal proceedings,
goodwill, patents, trade names, copyrights, trademarks, blueprints, drawings,
purchase orders, computer programs, computer disks, computer tapes, literature,
reports, catalogs and deposit accounts) other than goods and Receivables, as
well as Borrower's Books relating to any of the foregoing.

     1.18 "Inventory" as used in this Agreement means and includes all present
and future inventory in which Borrower has any interest, including, but not
limited to, goods held by Borrower for sale or lease or to be furnished under
a contract of service and all of Borrower's present and future raw materials,
work in process, finished goods, advertising materials, and packing and
shipping materials, wherever located and any documents of title representing
any of the above, and any equipment, fixtures or other property used in the
storing, moving, preserving, identifying, accounting for and shipping or
preparing for the shipping of inventory, and any and all other items hereafter
acquired by Borrower by way of substitution,

                                       2.
<PAGE>   3
                                REVOLVING CREDIT
                           LOAN & SECURITY AGREEMENT
                             (Accounts & Inventory)

replacement, return, repossession or otherwise, and all additions and
accessions thereto, and the resulting product or mass, and any documents of
title respecting any of the above.

        1.19 "Net Income" as used in this Agreement means the net income (or
loss) of a person for any period determined in accordance with GAAP but
excluding in any event:

        (a) any gains or losses on the sale or other disposition, not in the
        ordinary course of business, of investments or fixed or capital assets,
        and any taxes on the excluded gains and any tax deductions or credits on
        account on any excluded losses; and

        1.20 "Judicial Officer or Assignee" as used in this Agreement means and
includes any trustee, receiver, controller, custodian, assignee for the benefit
of creditors or any other person or entity having powers or duties like or
similar to the powers and duties of trustee, receiver, controller, custodian or
assignee for the benefit of creditors.

        1.21 "Obligations" as used in this Agreement means and includes any and
all loans, advances, overdrafts, debts, liabilities (including, without
limitation, any and all amounts charged to Borrower's account pursuant to any
agreement authorizing Bank to charge Borrower's account), obligations, lease
payments, guaranties, covenants and duties owing by Borrower to Bank of any
kind and description whether advanced pursuant to or evidenced by this
Agreement; by any note or other instrument; or by any other agreement between
Bank and Borrower and whether or not for the payment of money, whether direct
or indirect, absolute or contingent, due or to become due, now existing or
hereafter arising, and including, without limitation, any debt, liability owing
from Borrower to others which Bank may have obtained by assignment,
participation, purchase or otherwise, and further including, without
limitation, all interest not paid when due and all Bank Expenses which Borrower
is required to pay or reimburse by this Agreement, by law, or otherwise.

        1.22 "Person" or "person" as used in this Agreement means and includes
any individual, corporation, partnership, joint venture, association, trust,
unincorporated association, joint stock company, government, municipality,
political subdivision or agency, or other entity.

        1.23 "Receivables" as used in this Agreement means and includes all
presently existing and hereafter arising accounts, instruments, documents,
chattel paper, general intangibles, all other forms of obligations owing to
Borrower, all of Borrower's rights in, to and under all purchase orders
heretofore or hereafter received, all moneys due to Borrower under all
contracts or agreements (whether or not yet earned or due), all merchandise
returned to or reclaimed by Borrower and the Borrower's books (except minute
books) relating to any of the foregoing.

        1.24 "Subordinated Debt" as used in this Agreement means indebtedness of
the Borrower to third parties which has been subordinated to the Obligations
pursuant to a subordination agreement in form and content satisfactory to the
Bank.

        1.25 "Subordination Agreement" as used in this Agreement means a
subordination agreement in form satisfactory to Bank making all present and
future indebtedness of the Borrower to N/A subordinate to the Obligations.

        1.26 "Tangible Effective Net Worth" as used in this Agreement means net
worth as determined in accordance with GAAP consistently applied, increased by
Subordinated Debt, if any, and decreased by the following: patents, licenses,
goodwill, subscription lists, organization expenses, trade receivables
converted to notes, money due from affiliates (including officers, directors,
subsidiaries and commonly held companies).

        1.27 "Tangible Net Worth" as used in this Agreement means, as of any
applicable date of determination, the excess of

        a. the net book value of all assets of a person (other than patents,
        patent rights, trademarks, trade names, franchises, copyrights,
        licenses, goodwill, and similar intangible assets) after all appropriate
        deductions in accordance with GAAP (including, without limitation,
        reserves for doubtful receivables, obsolescence, depreciation and
        amortization), over

        b. all Debt of such person.

        1.28 "Total Liabilities" as used in this Agreement means the total of
all items of indebtedness, obligation or liability which, in accordance with
GAAP consistently applied, would be included in determining the total
liabilities of the Borrower as of the date Total Liabilities is to be
determined, including without limitation (a) all obligations secured by any
mortgage, pledge, security interest or other lien on property owned or
acquired, whether or not the obligations secured thereby shall have been
assumed; (b) all obligations which are capitalized lease obligations; and (c)
all guaranties, endorsements or other contingent or surety obligations with
respect to the indebtedness of others, whether or not reflected on the balance
sheets of the Borrower, including any obligation to furnish funds, directly or
indirectly through the purchase of goods, supplies, services, or by way of
stock purchase, capital contribution, advance or loan or any obligation to
enter into a contract for any of the foregoing.

        1.29 "Working Capital" as used in this Agreement means, as of any
applicable date of determination, Current Assets less Current Liabilities.

                                       3.
<PAGE>   4
                                REVOLVING CREDIT
                           LOAN & SECURITY AGREEMENT
                             (Accounts & Inventory)

     1.30 Any and all terms used in this Agreement shall be construed and
defined in accordance with the meaning and definition of such terms under and
pursuant to the California Uniform Commercial Code (hereinafter referred to as
the "Code") as amended.

2.   LOAN AND TERMS OF PAYMENT

     For value received, Borrower promises to pay to the order of Bank such
     amount, as provided for below, together with interest, as provided for
     below.

     2.1  Upon the request of Borrower, made at any time and from time to time
during the term hereof, and so long as no Event of Default has occurred, Bank
shall lend to Borrower an amount equal to the Borrowing Base; provided,
however, that in no event shall Bank be obligated to make advances to Borrower
under this Section 2.1 whenever the Daily Balance exceeds, at any time, either
the Borrowing Base or the sum of Five Million and no/100 ($5,000,000.00), such
amount being referred to herein as an "Overadvance".

     2.2  Except as hereinbelow provided, the Credit shall bear interest, on
the Daily Balance owing, at a rate of Zero (0.000) percentage points per annum
above the Base Rate (the "Rate"). The Credit shall bear interest, from and after
the occurrence of an Event of Default and without constituting a waiver of any
such Event of Default, on the Daily Balance owing, at a rate three (3)
percentage points per annum above the Rate. All interest chargeable under this
Agreement that is based upon a per annum calculation shall be computed on the
basis of a three hundred sixty (360) day year for actual days elapsed.

     The Base Rent as of the date of this Agreement is Eight and 5/10 (8.500%)
per annum. In the event that the Base Rent announced is, from time to time
hereafter changed, adjustment in the Rate shall be made and based on the Base
Rate in effect on the date of such change. The Rate, as adjusted, shall apply
to the Credit until the Base Rate is adjusted again. The minimum interest
payable by the Borrower under this Agreement shall in no event be less than N/A
per month. All interest payable by Borrower under the Credit shall be due and
payable on the first day of each calendar month during the term of this
Agreement. A late payment charge equal to 5% of each late payment may be
charged on any payment not received by the Bank within 10 calendar days after
the payment due date, but acceptance of payment of this charge shall not waive
any Default under this Agreement.

     2.3  Without affecting Borrower's obligation to repay immediately any
Overadvance in accordance with Section 2.1 hereof, all Overadvances shall bear
additional interest on the amount thereof at a rate equal to N/A (N/A%)
percentage points per month in excess of the interest rate set forth in Section
2.2, from the date incurred and for each month thereafter, until repaid in full.

3.   TERM.

     3.1  This Agreement shall remain in full force and effect until June 1,
2000, or until terminated by notice by Borrower. Notice of such termination by
Borrower shall be effectuated by mailing of a registered or certified letter not
less than thirty (30) days prior to the effective date of such termination,
addressed to the Bank at the address set forth herein and the termination shall
be effective as of the date so fixed in such notice. Notwithstanding the
foregoing, should Borrower be in default of one or more of the provisions of
this Agreement, Bank may terminate this Agreement at any time without notice.
Notwithstanding the foregoing, should either Bank or Borrower become insolvent
or unable to meet its debts as they mature, or fail, suspend, or go out of
business, the other party shall have the right to terminate this Agreement at
any time without notice. On the date of termination all Obligations shall become
immediately due and payable without notice or demand; no notice of termination
by Borrower shall be effective until Borrower shall have paid all Obligations to
Bank in full. Notwithstanding termination, until all Obligations have been fully
satisfied, Bank shall retain its security interest in all existing Collateral
and Collateral arising thereafter, and Borrower shall continue to perform all of
its Obligations.

     3.2  After termination and when Bank has received payment in full of
Borrower's Obligations to Bank, Bank shall reassign to Borrower all Collateral
held by Bank, and shall execute a termination of all security agreements and
security interests given by Borrower to Bank, upon the execution and delivery
of mutual general releases.

4.   CREATION OF SECURITY INTEREST

     4.1  Borrower hereby grants to Bank a continuing security interest in all
presently existing and hereafter arising Collateral in order to secure prompt
repayment of any and all Obligations owed by Borrower to Bank and in order to
secure prompt performance by Borrower of each and all of its covenants and
Obligations under this Agreement and otherwise created. Bank's security
interest in the Collateral shall attach to all Collateral without further act
on the part of Bank or Borrower. In the event that any Collateral, including
proceeds, is evidenced by or consists of a letter of credit, advice of credit,
instrument, money, negotiable documents, chattel paper or similar property
(collectively, "Negotiable Collateral"), Borrower shall, immediately upon
receipt thereof, endorse and assign such Negotiable Collateral over to Bank and
deliver actual physical possession of the Negotiable Collateral to Bank.

     4.2  Bank's security interest in Receivables shall attach to all
Receivables without further act on the part of Bank or Borrower. Upon request
from Bank, Borrower shall provide Bank with schedules describing all
Receivables created or acquired by Borrower (including without limitation agings
listing the names and addresses of, and amounts owing by date by account
debtors), and shall execute and deliver written assignments of all Receivables
to Bank all in a form acceptable to Bank, provided, however, Borrower's failure
to execute and deliver such schedules and/or assignments shall not affect or
limit Bank's security interest and other rights in and to the Receivables.
Together with each schedule,

                                       4.
<PAGE>   5
                                REVOLVING CREDIT
                           LOAN & SECURITY AGREEMENT
                             (Accounts & Inventory)

     Borrower shall furnish Bank with copies of Borrower's customers' invoices
     or the equivalent, and original shipping or delivery receipts for all
     merchandise sold, and Borrower warrants the genuineness thereof. Bank or
     Bank's designee may notify customers or account debtors of collection costs
     and expenses to Borrower's account but, unless and until Bank does so or
     gives Borrower other written instructions, Borrower shall collect all
     Receivables for Bank, receive in trust all payments thereon as Bank's
     trustee, and, if so requested to do so from Bank, Borrower shall
     immediately deliver said payments to Bank in their original form as
     received from the account debtor and all letters of credit, advices of
     credit, instruments, documents, chattel paper or any similar property
     evidencing or constituting Collateral. Notwithstanding anything to the
     contrary contained herein, if sales of Inventory are made for cash,
     Borrower shall immediately deliver to Bank, in identical form, all such
     cash, checks, or other forms of payment which Borrower receives. The
     receipt of any check or other item of payment by Bank shall not be
     considered a payment on account until such check or other item of payment
     is honored when presented for payment, in which event, said check or other
     item of payment shall be deemed to have been paid to Bank Two (2) calendar
     days after the date Bank actually receives such check or other item of
     payment.

          4.3  Bank's security interest in Inventory shall attach to all
     Inventory without further act on the part of Bank or Borrower. Upon Bank's
     request Borrower will from time to time at Borrower's expense pledge,
     assemble and deliver such Inventory to Bank or to a third party as Bank's
     bailee; or hold the same in trust for Bank's account or store the same in
     a warehouse in Bank's name; or deliver to Bank documents of title
     representing said Inventory; or evidence of Bank's security interest in
     some other manner acceptable to Bank. Until a default by Borrower under
     this Agreement or any other Agreement between Borrower and Bank, Borrower
     may, subject to the provisions hereof and consistent herewith, sell the
     Inventory, but only in the ordinary course of Borrower's business. A sale
     of Inventory in Borrower's ordinary course or business does not include an
     exchange or a transfer in partial or total satisfaction of a debt owing by
     Borrower.

          4.4  Borrower shall execute and deliver to Bank concurrently with
     Borrower's execution of this Agreement, and at any time or times hereafter
     at the request of Bank, all financing statements, continuation financing
     statements, security agreements, mortgages, assignments, certificates of
     title, affidavits, reports, notices, schedules of accounts, letters of
     authority and all other documents that Bank may request, in form
     satisfactory to Bank, to perfect and maintain perfected Bank's security
     interest in the Collateral and in order to fully consummate all of the
     transactions contemplated under this Agreement. Borrower hereby
     irrevocably makes, constitutes and appoints Bank (and any of Bank's
     officers, employees or agents designated by Bank) as Borrower's true and
     lawful attorney-in-fact with power to sign the name of Borrower on any
     financing statements, continuation financing statements, security
     agreement, mortgage, assignment, certificate of title, affidavit, letter
     of authority, notice of other similar documents which must be executed
     and/or filed in order to perfect or continue perfected Bank's security
     interest in the Collateral.

          Borrower shall make appropriate entries in Borrower's Books disclosing
     Bank's security interest in the Receivables. Bank (through any of its
     officers, employees or agents) shall have the right at any time or times
     hereafter during Borrower's usual business hours, or during the usual
     business hours of any third party having control over the records of
     Borrower, to inspect and verify Borrower's Books in order to verify the
     amount or condition of, or any other matter, relating to, said Collateral
     and Borrower's financial condition.

          4.5  Borrower appoints Bank or any other person whom Bank may
     designate as Borrower's attorney-in-fact, with power to endorse Borrower's
     name on any checks, notes, acceptances, money order, drafts or other forms
     of payment or security that may come into Bank's possession; to sign
     Borrower's name on any invoice or bill of lading relating to any
     Receivables, on drafts against account debtors, on schedules and
     assignments of Receivables, on verifications of Receivables and on notices
     to account debtors; to establish a lock box arrangement and/or to notify
     the post office authorities to change the address for delivery of
     Borrower's mail addressed to Borrower to an address designated by Bank, to
     receive and open all mail addressed to Borrower, and to retain all mail
     relating to the Collateral and forward all other mail to Borrower; to
     send, whether in writing or by telephone, requests for verification of
     Receivables; and to do all things necessary to carry out this Agreement.
     Borrower ratifies and approves all acts of the attorney-in-fact. Neither
     Bank nor its attorney-in-fact will be liable for any act or omissions or
     for any error of judgement or mistake of fact or law. This power being
     coupled with an interest, is irrevocable so long as any Receivables in
     which Bank has a security interest remain unpaid and until the Obligations
     have been fully satisfied.

          4.6  In order to protect or perfect any security interest which Bank
     is granted hereunder, Bank may, in its sole discretion, discharge any lien
     or encumbrance or bond the same, pay any insurance, maintain guards,
     warehousemen, or any personnel to protect the Collateral, pay any service
     bureau, or, obtain any records, and all costs for the same shall be added
     to the Obligations and shall be payable on demand.

          4.7  Borrower agrees that Bank may provide information relating to
     this Agreement or relating to Borrower to Bank's parent, affiliates,
     subsidiaries and service providers.

5.   CONDITIONS PRECEDENT

          5.1  Conditions precedent to the making of the loans and the
     extension of the financial accommodations hereunder, Borrower shall
     execute, or cause to be executed, and deliver to Bank, in form and
     substance satisfactory to Bank and its counsel, the following:

               a.   This Agreement and other documents required by Bank;

               b.   Financing statements (Form UCC-1) in form satisfactory to
               Bank for filing and recording with the appropriate governmental
               authorities;

                                       5.

<PAGE>   6
                                REVOLVING CREDIT
                           LOAN & SECURITY AGREEMENT
                             (ACCOUNTS & INVENTORY)

               c. If Borrower is a corporation, then certified extracts from the
               minutes of the meeting of its board of directors, authorizing
               the borrowings and the granting of the security interest
               provided for herein and authorizing specific officers to execute
               and deliver the agreements provided for herein;

               d. If Borrower is a corporation, then a certificate of good
               standing showing that Borrower is in good standing under the
               laws of the state of its incorporation and certificates that
               Borrower is qualified to transact business and is in good
               standing in any other state in which it conducts business;

               e. If Borrower is a partnership, then a copy of Borrower's
               partnership agreement certified by each general partner of
               Borrower;

               f. UCC searches, tax lien and litigation searches, fictitious
               business statement filings, insurance certificates, notices or
               other similar documents which Bank may require and in such form
               as Bank may require, in order to reflect, perfect or protect
               Bank's first priority security interest in the Collateral and in
               order to fully consummate all of the transactions contemplated
               under this Agreement;

               g. Evidence that Borrower has obtained insurance and acceptable
               endorsements;

               h. Waivers executed by landlords and mortgagees of any real
               property on which any Collateral is located; and

               i. Warranties and representations of officers.

6.     WARRANTIES REPRESENTATIONS AND COVENANTS.

       6.1 If so requested by Bank, Borrower shall, at such intervals
designated by Bank, during the term hereof execute and deliver a Report of
Accounts Receivable or similar report, in form customarily used by Bank.
Borrower's Borrowing Base at all times pertinent hereto shall not be less than
the advances made hereunder. Bank shall have the right to recompute Borrower's
Borrowing Base in conformity with this Agreement.

       6.2 If any warranty is breached as to any account, or any account is not
paid in full by an account debtor within Ninety (90) days from the date of
invoice, or an account debtor disputes liability or makes any claim with
respect thereto, or a petition in bankruptcy or other application for relief
under the Bankruptcy Code or any other insolvency law is filed by or against an
account debtor, or an account debtor makes an assignment for the benefit of
creditors, becomes insolvent, fails or goes out of business, then Bank may deem
ineligible any and all accounts owing by that account debtor, and reduce
Borrower's Borrowing Base by the amount thereof. Bank shall retain its security
interest in all Receivables and accounts, whether eligible or ineligible, until
all Obligations have been fully paid and satisfied. Returns and allowances, if
any, as between Borrower and its customers, will be on the same basis and in
accordance with the usual customary practices of the Borrower, as they exist at
this time. Any merchandise which is returned by an account debtor or otherwise
recovered shall be set aside, marked with Bank's name, and Bank shall retain a
security interest therein. Borrower shall promptly notify Bank of all disputes
and claims and settle or adjust them on terms approved by Bank. After default
by Borrower hereunder, no discount, credit or allowance shall be granted to any
account debtor by Borrower and no return of merchandise shall be accepted by
Borrower without Bank's consent. Bank may, after default by Borrower, settle or
adjust disputes and claims directly with account debtors for amounts and upon
terms which Bank considers advisable, and in such cases Bank will credit
Borrower's account with only the net amounts received by Bank in payment of the
accounts, after deducting all Bank Expenses in connection therewith.

       6.3 Borrower warrants, represents, covenants and agrees that:

               a. Borrower has good and marketable title to the Collateral.
               Bank has and shall continue to have a first priority perfected
               security interest in and to the Collateral. The Collateral shall
               at all times remain free and clear of all liens, encumbrances
               and security interests (except those in favor of Bank).

               b. All accounts are and will, at all times pertinent hereto, be
               bona fide existing obligations created by the sale and delivery
               of merchandise or the rendition of services to account debtors
               in the ordinary course of business, free of liens, claims,
               encumbrances and security interests (except as held by Bank and
               except as may be consented to, in writing, by Bank) and are
               unconditionally owed to Borrower without defenses, disputes,
               offsets, counterclaims, rights of return or cancellation, and
               Borrower shall have received no notice of actual or imminent
               bankruptcy or insolvency of any account debtor at the time an
               account due from such account debtor is assigned to Bank.

               c. At the time each account is assigned to Bank, all property
               giving rise to such account shall have been delivered to the
               account debtor or to the agent for the account debtor for
               immediate shipment to, and unconditional acceptance by, the
               account debtor. Borrower shall deliver to Bank, as Bank may from
               time to time require, delivery receipts, customer's purchase
               orders, shipping instruction, bills of lading and any other
               evidence of shipping arrangements. Absent such a request by
               Bank, copies of all such documentation shall be held by Borrower
               as custodian for Bank.

      6.4 At the time each Eligible Account is assigned to Bank, all such
Eligible Accounts will be due and payable on terms set forth in Section 1.12,
or on such other terms approved in writing by Bank in advance of the creation
of such accounts and which are expressly set forth on the face of all invoices,
copies of which shall be held by Borrower as custodian for Bank, and no such
eligible account will then be past due.

                                       6.
<PAGE>   7
                                REVOLVING CREDIT
                           LOAN & SECURITY AGREEMENT
                            (ACCOUNTING & INVENTORY)

       6.5 Borrower shall keep the inventory only at the following locations,
while allowing demo. inventory to be at different locations: 3956 Sorrento
Valley Blvd., San Diego, CA; 13845-B Alton Pkwy, Irvine, CA; 9207 Eton Ave.,
Chatsworth, CA.

               a. Borrower, immediately upon demand by Bank therefor, shall now
               and from time to time hereafter, at such intervals as are
               requested by Bank, deliver to Bank, designations of inventory
               specifying Borrower's cost of inventory, the wholesale market
               value thereof and such other matters and information relating to
               the inventory as Bank may request;

               b. Borrower's inventory, valued at the lower of Borrower's cost
               or the wholesale market value thereof, at all times pertinent
               hereto shall not be less than N/A Dollars ($N/A) of which no less
               than N/A Dollars ($N/A) shall be in raw materials and finished
               goods;

               c. All of the inventory is and shall remain free from all
               purchase money or other security interests, liens or
               encumbrances, except as held by Bank;

               d. Borrower does now keep and hereafter at all times shall keep
               correct and accurate records itemizing and describing the kind,
               type, quality and quantity of the inventory, its cost therefor
               and selling price thereof, and the daily withdrawals therefrom
               and additions thereto, all of which records shall be available
               upon demand to any of the Bank's officers, agents and employees
               for inspection and copying;

               e. All inventory, now and hereafter at all times, shall be new
               inventory of good and merchantable quality free from defects;

               f. Inventory is not now and shall not at any time or times
               hereafter be located or stored with a bailee, warehouseman or
               other third party without Bank's prior written consent, and, in
               such event, Borrower will concurrently therewith cause any such
               bailee, warehouseman or other third party to issue and deliver
               to Bank, in a form acceptable to Bank, warehouse receipts in
               Bank's name evidencing the storage of inventory or other
               evidence of Bank's prior rights in the inventory. In any event,
               Borrower shall instruct any third party to hold all such
               inventory for Bank's account subject to Bank's security
               interests and its instructions; and

               g. Bank shall have the right upon demand now and/or at all times
               hereafter, during Borrower's usual business hours, to inspect
               and examine the inventory and to check and test the same as to
               quality, quantity, value and condition and Borrower agrees to
               reimburse Bank for Bank's reasonable costs and expenses in so
               doing.

       6.6 Borrower represents, warrants and covenants with Bank that Borrower
will not, without Bank's prior written consent:

               a. Grant a security interest in or permit a lien, claim or
               encumbrance upon any of the Collateral to any person,
               association, firm, corporation, entity or governmental agency or
               instrumentality;

               b. Permit any levy, attachment or restraint to be made affecting
               any of Borrower's assets;

               c. Permit any Judicial Officer or Assignee to be appointed or to
               take possession of any or all of Borrower's assets;

               d. Other than sales of inventory in the ordinary course of
               Borrower's business, to sell, lease, or otherwise dispose of,
               move, or transfer, whether by sale or otherwise, any of
               Borrower's assets;

               e. Change its name, business structure, corporate identity or
               structure; add any new fictitious names, liquidate, merge or
               consolidate with or into any other business organization;

               f. Move or relocate any Collateral;

               g. Acquire any other business organization;

               h. Enter into any transaction not in the usual course of
               Borrower's business;

               i. Make any investment in securities of any person, association,
               firm, entity, or corporation other than the securities of the
               United States of America;

               j. Make any change in Borrower's financial structure or in any
               of its business objectives, purposes or operations which would
               adversely effect the ability of Borrower to repay Borrower's
               Obligations;

               k. Incur any debts outside the ordinary course of Borrower's
               business except renewals or extensions of existing debts and
               interest thereon;

               l. Make any advance or loan except in the ordinary course of
               Borrower's business as currently conducted;

                                       7.
<PAGE>   8
                                REVOLVING CREDIT
                           LOAN & SECURITY AGREEMENT
                             (Accounts & Inventory)

m.   Make loans, advances or extensions of credit to any Person, except for
sales on open account and otherwise in the ordinary course of business;

n.   Guarantee or otherwise, directly or indirectly, in any way be or become
responsible for obligations of any other Person, whether by agreement to
purchase the indebtedness of any other Person, agreement for the furnishing of
funds to any other Person through the furnishing of goods, supplies or services,
by way of stock purchase, capital contribution, advance or loan, for the purpose
of paying or discharging (or causing the payment or discharge of) the
indebtedness of any other Person, or otherwise, except for the endorsement of
negotiable instruments by the Borrower in the ordinary course of business for
deposit or collection.

o.   (a) Sell, lease, transfer or otherwise dispose of properties and assets
having an aggregate book value of more than One Hundred Thousand and 00/100
Dollars ($100,000.00) (whether in one transaction or in a series of
transactions) except as to the sale of inventory in the ordinary course of
business; (b) change its name, consolidate with or merge into any other
corporation, permit another corporation to merge into it, acquire all or
substantially all the properties or assets of any other Person, enter into any
reorganization or recapitalization or reclassify its capital stock, or (c)
enter into any sale-leaseback transaction;

p.   Subordinate any indebtedness due to it from a person to indebtedness of
other creditors of such person;

q.   Purchase or hold beneficially any stock or other securities of, or make
any investment or acquire any interest whatsoever in, any other Person, except
for the common stock of the Subsidiaries owned by the Borrower on the date of
this Agreement and except for certificates of deposit with maturities of one
year or less of United States commercial banks with capital, surplus and
undivided profits in excess of $100,000,000 and direct obligations of the
United States Government maturing within one year from the date of acquisition
thereof; or

r.   Allow any fact, condition or event to occur or exist with respect to any
employee pension or profit sharing plans established or maintained by it which
might constitute grounds for termination of any such plan or for the court
appointment of a trustee to administer any such plan.

6.7  Borrower is not a merchant whose sales for resale of goods for personal,
family or household purposes exceeded seventy-five percent (75%) in dollar
volume of its total sales of all goods during the 12 months preceding the filing
by Bank of a financing statement describing the Collateral. At no time hereafter
shall Borrower's sales for resale of goods for personal, family or household
purposes exceed seventy-five percent (75%) in dollar volume of its total sales.

6.8  Borrower's sole place of business or chief executive office or residence
is located at the address indicated above and Borrower covenants and agrees
that it will not, during the term of this Agreement, without prior written
notification to Bank, relocate said sole place of business or chief executive
office or residence.

6.9  If Borrower is a corporation, Borrower represents, warrants and covenants
as follows:

     a.   Borrower will not make any distribution or declare or pay any dividend
     (in stock or in cash) to any shareholder or on any of its capital stock, of
     any class, whether now or hereafter outstanding, or purchase, acquire,
     repurchase, redeem or retire any such capital stock;

     b.   Borrower is and shall at all times hereafter be a corporation duly
     organized and existing in good standing under the laws of the state of its
     incorporation and qualified and licensed to do business in California or
     any other state in which it conducts its business;

     c.   Borrower has the right and power and is duly authorized to enter into
     this Agreement; and

     d.   The execution by Borrower of this Agreement shall not constitute a
     breach of any provision contained in Borrower's articles of incorporation
     or by-laws.

6.10 The execution of and performance by Borrower of all of the terms and
provisions contained in this Agreement shall not result in a breach of or
constitute an event of default under any agreement to which Borrower is now or
hereafter becomes a party.

6.11 Borrower shall promptly notify Bank in writing of its acquisition by
purchase, lease or otherwise of any after acquired property of the type
included in the Collateral, with the exception of purchases of Inventory in the
ordinary course of business, and with the exception of acquired property under
a cost of $100,000.

6.12 All assessments and taxes, whether real, personal or otherwise, due or
payable by, or imposed, levied or assessed against, Borrower or any of its
property have been paid, and shall hereafter be paid in full, before
delinquency. Borrower shall make due and timely payment or deposit of all
federal, state and local taxes, assessments or contributions required of it by
law, and will execute and deliver to Bank, on demand, appropriate certificates
attesting to the payment or deposit thereof. Borrower will make timely payment
or deposit of all F.I.C.A. payments and withholding taxes required of it by
applicable laws, and will upon request furnish Bank with proof satisfactory to
it that Borrower has made such payments or deposit. If Borrower fails to pay any
such assessment, tax, contribution, or make such deposit, or furnish the
required proof, Bank may, in its sole and absolute discretion and without notice
to Borrower,

                                       8.
<PAGE>   9

                                REVOLVING CREDIT
                           LOAN & SECURITY AGREEMENT
                             (Accounts & Inventory)

(i) make payment of the same or any part thereof; or (ii) set up such reserves
in Borrower's account as Bank deems necessary to satisfy the liability
therefor, or both. Bank may conclusively rely on the usual statements of the
amount owing or other official statements issued by the appropriate
governmental agency. Each amount so paid or deposited by Bank shall constitute
a Bank Expense and an additional advance to Borrower.

        6.13 There are no actions or proceedings pending by or against Borrower
or any guarantor of Borrower before any court of administrative agency and
Borrower has no knowledge of any pending, threatened or imminent litigation,
governmental investigations or claims, complaints, actions or prosecutions
involving Borrower or any guarantor of Borrower, except as heretofore
specifically disclosed in writing to Bank. If any of the foregoing arise during
the term of the Agreement, Borrower shall immediately notify Bank in writing.

        6.14 a. Borrower, at its expense, shall keep and maintain its assets
insured against loss or damage by fire, theft, explosion, sprinklers and all
other hazards and risks ordinarily insured against by other owners who use such
properties in similar businesses for the full insurable value thereof. Borrower
shall also keep and maintain business interruption insurance and public
liability and property damage insurance relating to Borrower's ownership and
use of the Collateral and its other assets. All such policies of insurance
shall be in such form, with such companies, and in such amounts as may be
satisfactory to Bank. Borrower shall deliver to Bank certified copies of such
policies of insurance and evidence of the payments of all premiums therefor.
All such policies of insurance (except those of public liability and property
damage) shall contain an endorsement in a form satisfactory to Bank showing
Bank as a loss payee thereof, with a waiver of warranties (Form 438-BFU), and
all proceeds payable thereunder shall be payable to Bank and, upon receipt by
Bank, shall be applied on account of the Obligations owing to Bank. To secure
the payment of the Obligations, Borrower grants Bank a security interest in and
to all such policies of insurance (except those of public liability and
property damage) and the proceeds thereof, and Borrower shall direct all
insurers under such policies of insurance to pay all proceeds thereof directly
to Bank.

b. Borrower hereby irrevocably appoints Bank (and any of Bank's officers,
employees or agents designated by Bank) as Borrower's attorney for the purpose
of making, selling and adjusting claims under such policies of insurance,
endorsing the name of Borrower on any check, draft, instrument or other item of
payment for the proceeds of such policies of insurance and for making all
determinations and decisions with respect to such policies of insurance.
Borrower will not cancel any of such policies without Bank's prior written
consent. Each such insurer shall agree by endorsement upon the policy or
policies of insurance issued by it to Borrower as required above, or by
independent instruments furnished to Bank, that it will give Bank at least ten
(10) days written notice before any such policy or policies of insurance shall
be altered or cancelled, and that no act or default of Borrower, or any other
person, shall affect the right of Bank to recover under such policy or policies
of insurance required above or to pay any premium in whole or in part relating
thereto Bank, without waiving or releasing any Obligations or any Event of
Default, may, but shall have no obligation to do so, obtain and maintain such
policies of insurance and pay such premiums and take any other action with
respect to such policies which Bank deems advisable. All sums so disbursed by
Bank, as well as reasonably attorneys' fees, court costs, expenses and other
charges relating thereto, shall constitute Bank Expenses and are payable on
demand.

        6.15 All financial statements and information relating to Borrower
which have been or may hereafter be delivered by Borrower to Bank are true and
correct and have been prepared in accordance with GAAP consistently applied
and there has been no material adverse change in the financial condition of
Borrower since the submission of such financial information to Bank.

        6.16 a. Borrower at all times hereafter shall maintain a standard and
modern system of accounting in accordance with GAAP consistently applied with
ledger and account cards and/or computer tapes and computer disks, computer
printouts and computer records pertaining to the Collateral which contain
information as may from time to time be requested by Bank, not modify or change
its method of accounting or enter into, modify or terminate any agreement
presently existing, or at any time hereafter entered into with any third party
accounting firm and/or service bureau for the preparation and/or storage of
Borrower's accounting records without the written consent of Bank first obtained
and without said accounting firm and/or service bureau agreeing to provide
information regarding the Receivables and Inventory and Borrower's financial
condition to Bank; permit Bank and any of its employees, officers or agents,
upon demand, during Borrower's usual business hours, or the usual business hour
of third parsons having control thereof, to have access to and examine all of
the Borrower's Books relating to the Collateral, Borrower's Obligations to
Bank, Borrower's financial condition and the results of Borrower's operations
and in connection therewith, permit Bank or any of its agents, employees or
officers to copy and make extracts therefrom.

b. Borrower shall deliver to Bank within forty-five (45) days after the end of
each Quarter, a COMPANY PREPARED balance sheet and profit and loss statement
covering Borrower's operations and deliver to Bank within ninety (90) days
after the end of each of Borrower's fiscal years a(n) AUDITED statement of the
financial condition of the Borrower for each such fiscal year, including but
not limited to, a balance sheet and profit and loss statement and any other
report requested by Bank relating to the Collateral and the financial condition
of Borrower, and a certificate signed by an authorized employee of Borrower to
the effect that all reports, statements, computer disk or tape files, computer
printouts, computer runs, or other computer prepared information of any kind or
nature relating to the foregoing or documents delivered or caused to be
delivered to Bank under this subparagraph are complete, correct and thoroughly
present the financial condition of Borrower and that there exists on the date
of delivery to Bank no condition or event which constitutes a breach or Event
of Default under this Agreement. See Addendum A attached.

                                       9.
<PAGE>   10
                                REVOLVING CREDIT
                           LOAN & SECURITY AGREEMENT
                             (Accounts & Inventory)

   C. In addition to the financial statements requested above, the Borrower
agrees to provide Bank with the following schedules:

         XX        Accounts Receivable Agings    on a Monthly         basis;
   ----------------                                   ----------------

         XX        Accounts Payable Agings       on a Monthly         basis;
   ----------------                                   ----------------

                   Job Progress Reports          on a                 basis; and
   ----------------                                   ----------------

         XX        Borrowing Base Certificates   on a Monthly         basis
   ----------------                                   ----------------

   See Addendum "A" attached for additional controls for subsidiaries

   6.17 Borrower shall maintain the following financial ratios and covenants on
a consolidated and non-consolidated basis:

   a. Working Capital in an amount not less than  N/A
                                                --------------------------------

   -----------------------------------------------------------------------------

   b. Tangible Effective Net Worth in an amount not less than  $9,000,000,
                                                              ------------------
   increasing to $9,500,000 at 3/31/00.
   -----------------------------------------------------------------------------

   c. a ratio of Current Assets to Current Liabilities of not less than

   1.75:1.00
   -----------------------------------------------------------------------------

   d. a quick ratio of cash plus securities plus Receivables to Current
   Liabilities of not less than  N/A
                               -------------------------------------------------

   -----------------------------------------------------------------------------

   e. a ratio of Total Liabilities (less debt subordinated to Bank) to Tangible
   Effective Net Worth of less than 1.25:1.00
                                   ---------------------------------------------

   -----------------------------------------------------------------------------

   f. a ratio of Cash Flow to Fixed Charges of not less than  N/A
                                                            --------------------

   -----------------------------------------------------------------------------

   g. Net Income after taxes of Net loss before one-time writeoffs for FYE
                                ------------------------------------------------
   12/31/99 of no greater than ($1,600,000). Minimum net income after taxes of
   -----------------------------------------------------------------------------
   $500,000 annually beginning 12/31/00. Quarterly net loss of no greater than
   -----------------------------------------------------------------------------
   ($450,000) for the quarter ending 3/31/00, ($50,000) quarterly thereafter.
   -----------------------------------------------------------------------------

   h. Borrower shall not without Bank's prior written consent acquire or expend
   for or commit itself to acquire or expend for fixed assets by lease, purchase
   or otherwise in an aggregate amount that exceeds  N/A
                                                   -----------------------------
                           Dollars ($            ) in any fiscal year; and
   ------------------------          ------------

   i. Monthly report of costs completed on the IBM Laser Station Contract.
   -----------------------------------------------------------------------------

   j. Semi-annual Accounts Receivable and Inventory Audit.k. Quarterly backlog
   -----------------------------------------------------------------------------
   report.
   -------

   All financial covenants shall be computed in accordance with GAAP
consistently applied except as otherwise specifically set forth in this
Agreement. All monies due from affiliates (including officers, directors and
shareholders) shall be excluded from Borrower's assets for all purposes
hereunder.

   6.18 Borrower shall promptly supply Bank (and cause any guarantor to supply
Bank) with such other information (including tax returns) concerning its
financial affairs (or that of any guarantor) as Bank may request from time to
time hereafter, and shall promptly notify Bank of any material adverse change
in Borrower's financial condition and of any condition or event which
constitutes a breach of or an event which constitutes an Event of Default under
this Agreement.

   6.19 Borrower is now and shall be at all times hereafter solvent and able to
pay its debts (including trade debts) as they mature.

   6.20 Borrower shall immediately and without demand reimburse Bank for all
sums expended by Bank in connection with any action brought by Bank to correct
any default or enforce any provision of this Agreement, including all Bank
Expenses; Borrower authorizes and approves all advances and payments by Bank
for items described in this Agreement as Bank Expenses.

   6.21 Each warranty, representation and agreement contained in this Agreement
shall be automatically deemed repeated with each advance and shall be
conclusively presumed to have been relied on by Bank regardless of any
investigation made or information possessed by Bank. The warranties,
representations and agreements set forth herein shall be cumulative and in
addition to any and all other warranties, representations and agreements which
Borrower shall give, or cause to be given, to Bank, either now or hereafter.

   6.22 Borrower shall keep all of its principal bank accounts with Bank and
shall notify the Bank immediately in writing of the existence of any other bank
account, deposit account, or any other account into which money can be
deposited.

   6.23 Borrower shall furnish to the Bank: (a) as soon as possible, but in no
event later than thirty (30) days after Borrower knows or has reason to know
that any reportable event with respect to any deferred compensation plan has
occurred, a statement of the chief financial officer of Borrower setting forth
the details concerning such reportable

                                      10.

<PAGE>   11
                                REVOLVING CREDIT
                           LOAN & SECURITY AGREEMENT
                             (Accounts & Inventory)

event and the action which Borrower proposes to take with respect thereto,
together with a copy of the notice of such reportable event given to the
Pension Benefit Guaranty Corporation, if a copy of such notice is available to
Borrower; (b) promptly after the filing thereof with the United States
Secretary of Labor or the Pension Benefit Guaranty Corporation, copies of each
annual report with respect to each deferred compensation plan; (c) promptly
after receipt thereof, a copy of any notice Borrower may receive from the
Pension Benefit Guaranty Corporation or the Internal Revenue Service with
respect to any deferred compensation plan; provided, however, this subparagraph
shall not apply to notice of general application issued by the Pension Benefit
Guaranty Corporation or the Internal Revenue Service; and (d) when the same is
made available to participants in the deferred compensation plan, all notices
and other forms of information from time to time disseminated to the
participants by the administrator of the deferred compensation plan.

       6.24 Borrower is now and shall at all times hereafter remain in
compliance with all federal, state and municipal laws, regulations and
ordinances relating to the handling, treatment and disposal of toxic
substances, wastes and hazardous material and shall maintain all necessary
authorizations and permits.

       6.25 Borrower shall maintain insurance on the life of          N/A
                                                             -------------------
                        in an amount not to be less than                 Dollars
-----------------------                                  ---------------
($                     ) under one or more policies issued by insurance
  ---------------------
companies satisfactory to Bank, which policies shall be assigned to Bank as
security for the Obligations and on which Bank shall be named as sole
beneficiary.

       6.26 Borrower shall limit direct and indirect compensation paid to the
following employees:                                ,                          ,
                     -------------------------------  -------------------------
to an aggregate of                             Dollars ($      N/A         ) per
                   ---------------------------           ------------------
               N/A                             .
-----------------------------------------------
       6.27 Borrower shall perform all acts reasonably necessary to ensure
that: (i) Borrower and any business in which Borrower holds a substantial
interest, and (ii) all customers, suppliers and vendors that are material to
Borrower's business, become Year 2000 Compliant in a timely manner. Such acts
shall include, without limitation, performing a comprehensive review and
assessment of all of Borrower's systems and adopting a detailed plan, with
itemized budget, for the remediation, monitoring and testing of such systems,
As used in this paragraph, "Year 2000 Compliant" shall mean, in regard to any
entity, that all software, hardware, firmware, equipment, goods or systems
utilized by or material to the business operations or financial condition of
such entity, will properly perform date sensitive function before, during and
after the year 2000. Borrower, shall, immediately upon request, provide to Bank
such certifications or other evidence of Borrower's compliance with terms of
this paragraph as Bank may from time to time require.

7.     EVENTS OF DEFAULT

       Any one or more of the following events shall constitute a default by
Borrower under this Agreement:

a. If Borrower fails or neglects to perform, keep or observe any term,
provision, condition, covenant, agreement, warranty or representation contained
in this Agreement, or any other present or future agreement between Borrower and
Bank;

b. If any representation, statement, report or certificate made or delivered by
Borrower, or any of its officers, employees or agents to Bank is not true and
correct;

c. If Borrower fails to pay when due and payable or declared due and payable,
all or any portion of the Borrower's Obligations (whether of principal,
interest, taxes, reimbursement of Bank Expenses, or otherwise);

d. If there is a material impairment of the prospect of repayment of all or any
portion of Borrower's Obligations or a material impairment of the value or
priority of Bank's security interest in the Collateral;

e. If all or any of Borrower's assets are attached, seized, subject to a writ or
distress warrant, or are levied upon, or come into the possession of any
Judicial Officer or Assignee and the same are not released, discharged or bonded
against within ten (10) days thereafter;

f. If any Insolvency Proceeding is filed or commenced by or against Borrower
without being dismissed within ten (10) days thereafter;

g. If any proceeding is filed or commenced by or against Borrower for its
dissolution or liquidation;

h. If Borrower is enjoined, restrained or in any way prevented by court order
from continuing to conduct all or any material part of its business affairs;

i. If a notice of lien, levy or assessment is filed of record with respect to
any or all of Borrower's assets by the United States Government, or any
department, agency or instrumentality thereof, or by any state, county,
municipal or other government agency, or if any taxes or debts owing at any time
hereafter to any one or more of such entities becomes a lien, whether choate or
otherwise, upon any or all of the Borrower's assets and the same is not paid on
the payment date thereof;

j. If a judgment or other claim becomes a lien or encumbrance upon any or all of
Borrower's assets and the same is not satisfied, dismissed or bonded against
within ten (10) days thereafter;

k. If Borrower's records are prepared and kept by an outside computer service
bureau at the time this Agreement is entered into or during the term of this
Agreement such an agreement with an outside service bureau is entered into, and
at any time thereafter, without first obtaining the written consent of Bank,
Borrower terminates, modifies, amends or changes its contractual relationship
with said computer service bureau or said computer service bureau fails to
provide Bank with any requested information or financial data pertaining to
Bank's Collateral, Borrower's financial condition or the results of Borrower's
operations;

                                      11.
<PAGE>   12

                                REVOLVING CREDIT
                           LOAN & SECURITY AGREEMENT
                             (Accounts & Inventory)

     l. If Borrower permits a default in any material agreement to which
     Borrower is a party with third parties so as to result an acceleration of
     the maturity of Borrower's indebtedness to others, whether under any
     indenture, agreement or otherwise;

     m. If Borrower makes any payment on account of indebtedness which has been
     subordinated to Borrower's Obligations to Bank;

     n. If any misrepresentation exists now or thereafter in any warranty or
     representation made to Bank by any officer or director of Borrower, or if
     any such warranty or representation is withdrawn by any officer or
     director;

     o. If any party subordinating its claims to that of Bank's or any guarantor
     of Borrower's Obligations dies or terminates its subordination or guaranty,
     becomes insolvent or an insolvency Proceeding is commenced by or against
     any such subordinating party or guarantor;

     p. If Borrower is an individual and Borrower dies;

     q. If there is a change of ownership or control of N/A percent (N/A%) or
     more of the issued and outstanding stock of Borrower; or

     r. If any reportable event, which the Bank determines constitutes grounds
     for the termination of any deferred compensation plan by the Pension
     Benefit Guaranty Corporation or for the appointment by the appropriate
     United States District Court of a trustee to administer any such plan,
     shall have occurred and be continuing thirty (30) days after written notice
     of such determination shall have been given to Borrower by Bank, or any
     such Plan shall be terminated within the meaning of Title IV of the
     Employment Retirement Income Security Act ("ERISA"), or a trustee shall be
     appointed by the appropriate United States District Court to administer any
     such plan, or the Pension Benefit Guaranty Corporation shall institute
     proceedings to terminate any plan and in case of any event described in
     this Section 7.0, the aggregate amount of the Borrower's liability to the
     Pension Benefit Guaranty Corporation under Sections 4062, 4063 or 4064 of
     ERISA shall exceed five percent (5%) of Borrower's Tangible Effective Net
     Worth.

          Notwithstanding anything contained in Section 7 to the contrary, Bank
     shall refrain from exercising its rights and remedies and Events of Default
     shall thereafter not be deemed to have occurred by reason of the occurrence
     of any of the events set forth in Sections 7.e, 7.f or 7.j of this
     Agreement if, within ten (10) days from the date thereof, the same is
     released, discharged, dismissed, bonded against or satisfied; provided,
     however, if the event is the institution of insolvency Proceedings against
     Borrower, Bank shall not be obligated to make advances to Borrower during
     such cure period.

8.   BANK'S RIGHTS AND REMEDIES

          8.1 Upon the occurrence of an Event of Default by Borrower under this
     Agreement, Bank may, at its election, without notice of its election and
     without demand, do any one or more of the following, all of which are
     authorized by Borrower:

          a. Declare Borrower's Obligations, whether evidenced by this
          Agreement, Installment notes, demand notes or otherwise, immediately
          due and payable to the Bank;

          b. Cease advancing money or extending credit to or for the benefit of
          Borrower under this Agreement, or any other agreement between
          Borrower and Bank;

          c. Terminate this Agreement as to any future liability or obligation
          of Bank, but without affecting Bank's rights and security interests
          in the Collateral, and the Obligations of Borrower to Bank;

          d. Without notice to or demand upon Borrower or any guarantor, make
          such payments and do such acts as Bank considers necessary or
          reasonable to protect its security interest in the Collateral.
          Borrower agrees to assemble the Collateral if Bank so requires and to
          make the Collateral available to Bank as Bank may designate. Borrower
          authorizes Bank to enter the premises where the Collateral is
          located, take and maintain possession of the Collateral and the
          premises (at no charge to Bank), or any part thereof, and to pay,
          purchase, contest or compromise any encumbrance, charge or lien which
          in the opinion of Bank appears to be prior or superior to its
          security interest and to pay all expenses incurred in connection
          therewith;

          e. Without limiting Bank's rights under any security interest, Bank
          is hereby granted a license or other right to use, without charge,
          Borrower's labels, patents, copyrights, rights of use of any name,
          trade secrets, trade names, trademarks and advertising matter, or any
          property of a similar nature as it pertains to the Collateral, in
          completing production of, advertising for sale and selling any
          Collateral and Borrower's rights under all licensees and all
          franchise agreement shall inure to Bank's benefit, and Bank shall
          have the right and power to enter into sublicense agreements with
          respect to all such rights with third parties on terms acceptable to
          Bank;

          f. Ship, reclaim, recover, store, finish, maintain, repair, prepare
          for sale, advertise for sales and sell (in the manner provided for
          herein) the inventory;

          g. Sell or dispose the Collateral at either a public or private sale,
          or both, by way of one or more contracts or transactions, for cash or
          on terms, in such manner and at such places (including Borrower's
          premises) as is commercially reasonable in the opinion of Bank. It is
          not necessary that the Collateral be present at any such sale;

          h. Bank shall give notice of the disposition of the Collateral as
          follows:

                                      12.
<PAGE>   13
                                REVOLVING CREDIT
                           LOAN & SECURITY AGREEMENT
                             (Accounts & Inventory)

               (1)  Bank shall give the Borrower and each holder of a security
               interest in the Collateral who has filed with Bank a written
               request for notice, a notice in writing of the time and place of
               public sale, or, if the sale is a private sale or some
               disposition other than a public sale is to be made of the
               Collateral, the time on or after which the private sale or other
               disposition is to be made;

               (2)  The notice shall be personally delivered or mailed, postage
               prepaid, to Borrower's address appearing in this Agreement, at
               least five (5) calendar days before the date fixed for the sale,
               or at least five (5) calendar days before the date on or after
               which the private sale or other disposition is to be made, unless
               the Collateral is perishable or threatens to decline speedily in
               value. Notice to persons other than Borrower claiming an interest
               in the Collateral shall be sent to such addresses as they have
               furnished to Bank;

               (3)  If the sale is to be a public sale, Bank shall also give
               notice of the time and place by publishing a notice one time at
               least five (5) calendar days before the date of the sale in a
               newspaper of general circulation in the county in which the sale
               is to be held; and

               (4)  Bank may credit bid and purchase at any public sale.

          i. Borrower shall pay all Bank Expenses incurred in connection with
          Bank's enforcement and exercise of any of its rights and remedies as
          herein provided, whether or not suit is commenced by Bank;

          j. Any deficiency which exists after disposition of the Collateral
          as provided above will be paid immediately by Borrower. Any excess
          will be returned, without interest and subject to the rights of third
          parties, to Borrower by Bank, or, in Bank's discretion, to any party
          who Bank believes, in good faith, is entitled to the excess; and

          k. Without constituting a retention of Collateral in satisfaction of
          an obligation within the meaning of 9505 of the Uniform Commercial
          Code or an action under California Code of Civil Procedure 726, apply
          any and all amounts maintained by Borrower as deposit accounts (as
          that term is defined under 9105 of the Uniform Commercial Code) or
          other accounts that Borrower maintains with Bank against the
          Obligations.

          8.2  Bank's rights and remedies under this Agreement and all other
     agreements shall be cumulative. Bank shall have all other rights and
     remedies not inconsistent herewith as provided by law or in equity. No
     exercise by Bank of one right or remedy shall be deemed an election, and no
     waiver by Bank of any default on Borrower's part shall be deemed a
     continuing waiver. No delay by Bank shall constitute a waiver, election or
     acquiescence by Bank.

9.   TAXES AND EXPENSES REGARDING BORROWER'S PROPERTY.

If Borrower fails to pay promptly when due to another person or entity, monies
which Borrower is required to pay by reason of any provision in this Agreement,
Bank may, but need not, pay the same and charge Borrower's account therefor,
and Borrower shall promptly reimburse Bank. All such sums shall become
additional indebtedness owing to Bank, shall bear interest at the rate
hereinabove provided, and shall be secured by all Collateral. Any payments made
by Bank shall not constitute (i) an agreement by it to make similar payments in
the future; or (ii) a waiver by Bank of any default under this Agreement. Bank
need not inquire as to, or contest the validity of, any such expense, tax,
security interest, encumbrance or lien and the receipt of the usual official
notice of the payment thereof shall be conclusive evidence that the same was
validly due and owing. Such payments shall constitute Bank Expenses and
additional advances to Borrower.

10.  WAIVERS.

          10.1 Borrower agrees that checks and other instruments received by
     Bank in payment or on account of Borrower's Obligations constitute only
     conditional payment until such items are actually paid to Bank and
     Borrower waives the right to direct the application of any and all
     payments at any time or times thereafter received by Bank on account of
     Borrower's Obligations and Borrower agrees that Bank shall have the
     continuing exclusive right to apply and reapply such payments in any
     manner as Bank may deem advisable, notwithstanding any entry by Bank upon
     its books.

          10.2 Borrower waives demand, protest, notice of protest, notice of
     default or dishonor, notice of payment and nonpayment, notice of any
     default, nonpayment at maturity, release, compromise, settlement,
     extension or renewal or any or all commercial paper, accounts, documents,
     instruments chattel paper, and guarantees at any time held by Bank on
     which Borrower may in any way be liable.

          10.3 Bank shall not in any way or manner be liable or responsible for
     (a) the safekeeping of the Inventory; (b) any loss or damage thereto
     occurring or arising in any manner or fashion from any cause; (c) any
     diminution in the value thereof; or (d) any act or default of any carrier,
     warehouseman, bailee, forwarding agency or other person whomsoever. All
     risk of loss, damage or destruction of Inventory shall be borne by
     Borrower.

          10.4 Borrower waives the right and the right to assert a confidential
     relationship, if any, it may have with any accountant, accounting firm
     and/or service bureau or consultant in connection with any information
     requested by Bank pursuant to or in accordance with this Agreement, and
     agrees that a Bank may contact directly any such accountants, accounting
     firm and/or service bureau or consultant in order to obtain such
     information.

          10.5 BORROWER AND BANK EACH WAIVE ANY RIGHT TO TRIAL BY JURY IN ANY
     ACTION OR PROCEEDING RELATING TO THIS AGREEMENT OR ANY TRANSACTION
     HEREUNDER, OR CONTEMPLATED HEREUNDER, OR ANY OTHER CLAIM (INCLUDING TORT
     OR BREACH OF DUTY CLAIMS) OR DISPUTE HOWSOEVER ARISING BETWEEN BANK AND
     BORROWER.

                                      13.

<PAGE>   14
                                REVOLVING CREDIT
                           LOAN & SECURITY AGREEMENT
                             (Accounts & Inventory)

     10.6  In the event that Bank elects to waive any rights or remedies
     hereunder, or compliance with any of the terms hereof, or delays or fails
     to pursue or enforce any terms, such waiver, delay or failure to pursue or
     enforce shall only be effective with respect to that single act and shall
     not be construed to affect any subsequent transactions or Bank's right to
     later pursue such rights and remedies.

11.  ONE CONTINUING LOAN TRANSACTION.

All loans and advances heretofore, now or at any time or times hereafter made
by Bank to Borrower under this Agreement or any other agreement between Bank
and Borrower, shall constitute one loan secured by Bank's security interests
in the Collateral and by all other security interests, liens, encumbrances
heretofore, now or from time to time hereafter granted by Borrower to Bank.

Notwithstanding the above, (i) to the extent that any portion of the
Obligations are a consumer loan, that portion shall not be secured by any deed
of trust or mortgage on or other security interest in Borrower's principal
dwelling which is not a purchase money security interest as to that portion,
unless expressly provided to the contrary in another place, or (ii) if the
Borrower (or any of them) has (have) given or give(s) Bank a deed of trust or
mortgage covering real property, that deed of trust or mortgage shall not
secure the loan and any other Obligation of the Borrower (or any of them),
unless expressly provided to the contrary in another place.

12.  NOTICES.

Unless otherwise provided in this Agreement, all notices or demands by either
party on the other relating to this Agreement shall be in writing and sent by
regular United States mail, postage prepaid, properly addressed to Borrower or
to Bank at the addresses stated in this Agreement, or to such other addresses
as Borrower or Bank may from time to time specify to the other in writing.
Requests to Borrower by Bank hereunder may be made orally.

13.  AUTHORIZATION TO DISBURSE.

Bank is hereby authorized to make loans and advances hereunder upon telephonic
or other instructions received from anyone purporting to be an officer,
employee, or representative of Borrower, or at the discretion of Bank if said
loans and advances are necessary to meet any Obligations of Borrower to Bank.
Bank shall have no duty to make inquiry or verify the authority of any such
party, and Borrower shall hold Bank harmless from any damage, claims or
liability by reason of Bank's honor of, or failure to honor, any such
instructions.

14.  DESTRUCTION OF BORROWER'S DOCUMENTS.

Any documents, schedules, invoices or other papers delivered to Bank, may be
destroyed or otherwise disposed of by Bank six (6) months after they are
delivered to or received by Bank, unless Borrower requests, in writing, the
return of the said documents, schedules, invoices or other papers and makes
arrangements, at Borrower's expense, for their return.

15.  CHOICE OF LAW.

The validity of this Agreement, its construction, interpretation and
enforcement, and the rights of the parties hereunder and concerning the
Collateral, shall be determined according to the laws of the State of
California. The parties agree that all actions or proceedings arising in
connection with this Agreement shall be tried and litigated only in the state
and federal courts in the Northern District of California or County of Santa
Clara.

16.  GENERAL PROVISIONS.

          16.1  This Agreement shall be binding and deemed effective when
     executed by the Borrower and accepted and executed by Bank at its
     Headquarter Office.

          16.2  This Agreement shall bind and inure to the benefit of the
     respective successors and assigns of each of the parties, provided,
     however, that Borrower may not assign this Agreement or any rights
     hereunder without Bank's prior written consent and any prohibited
     assignment shall be absolutely void. No consent to an assignment by Bank
     shall release Borrower or any guarantor from their Obligations to Bank.
     Bank may assign this Agreement and its rights and duties hereunder. Bank
     reserves the right to sell, assign, transfer, negotiate or grant
     participations in all or any part of, or any interest in Bank's rights and
     benefits hereunder. In connection therewith, Bank may disclose all
     documents and information which Bank now or hereafter may have relating to
     Borrower or Borrower's business.

          16.3  Paragraph headings and paragraph numbers have been set forth
     herein for convenience only; unless the contrary is compelled by the
     context, everything contained in each paragraph applies equally to this
     entire Agreement.

          16.4  Neither this Agreement nor any uncertainty or ambiguity herein
     shall be construed or resolved against Bank or Borrower, whether under any
     rule of construction or otherwise; on the contrary, this Agreement has been
     reviewed by all parties and shall be construed and interpreted according to
     the ordinary meaning of the words used so as to fairly accomplish the
     purposes and intentions of all parties hereto. When permitted by the
     context, the singular includes the plural and vice versa.

                                      14.
<PAGE>   15
                                REVOLVING CREDIT
                           LOAN & SECURITY AGREEMENT
                             (Accounts & Inventory)

     16.5 Each provision of this Agreement shall be severable from every other
provision of this Agreement for the purpose of determining the legal
enforceability of any specific provision.

     16.6 This Agreement cannot be changed or terminated orally. Except as to
currently existing Obligations owing by Borrower to Bank, all prior agreements,
understandings, representations, warranties, and negotiations, if any, with
respect to the subject matter hereof, are merged into this Agreement.

     16.7 The parties intend and agree that their respective rights, duties,
powers, liabilities, obligations and discretions shall be performed, carried
out, discharged and exercised reasonably and in good faith.

     IN WITNESS WHEREOF, the parties hereto have caused this Revolving Credit
Loan & Security Agreement (Accounts and Inventory) to be executed as of the
date first hereinabove written.

ATTEST:                            BORROWER: JMAR Technologies, Inc.

-------------------------------    By: /s/ Dennis E. Valentine
Title                                 --------------------------------
                                      Signature of Dennis E. Valentine

Accepted and effective as of
December 20, 1999                  Title: Chief Financial Officer
-------------------------------           -----------------------------
at Bank's Headquarter Office

(Bank) Comerica Bank-California

By:                                By: /s/ Brock Mullins
   ----------------------------        -------------------------------
   Signature of Brock Mullins

Title: Vice President              Title:
     --------------------------          -----------------------------

                                   By:
                                      --------------------------------
                                       Signature of

                                   Title:
                                        ------------------------------

                                      15.
<PAGE>   16
           Addendum "A" to Revolving Credit Loan & Security Agreement

                            Dated December 20, 1999

Section 1.5 is amended by adding the following:

     ...Plus (3) 50% of unbilled revenue on IBM Laser Station contract up to a
maximum advance of $750,000, plus (4) $750,000 overformula to be reduced to $0
for 30 consecutive days annually.

Section 1.12 is amended by substituting the following underlined passage for
"Borrower":

        1.12 "Eligible Accounts" as used in this Agreement means and includes
those accounts of JMAR Precision Systems which ...

Section 1.12(c) is hereby deleted in its entirety and replaced with the
following:

     (c)  accounts with respect to which the account debtor is not a resident
of the United States, except that account debtors that are foreign subsidiaries
of IBM shall be eligible up to an aggregate of $500,000.00.

Section 1.12(k) is hereby deleted in its entirety and replaced with the
following:

     (k)  accounts owed by any single account debtor which exceed twenty
percent (20% of all of the Eligible Accounts, except that with respect to
account debtor Affymetrix, Inc. the accounts owed by them shall not exceed
sixty percent (60%) and account debtor IBM (combined foreign and domestic) the
accounts owed by them shall not exceed fifty percent (50%).

Section 6.16(b) is hereby deleted in its entirety and replaced with the
following:

      b.  Borrower shall deliver to Bank within Forty-five (45) days after the
end of each Quarter, a consolidated and consolidating company-prepared balance
sheet and profit and loss statement covering Borrower's and JMAR Precision
Systems' operations and deliver to Bank within ninety (90) days after the end
of each of Borrower's fiscal years a consolidated and consolidating audited
statement of the financial condition of the Borrower for each such fiscal year,
including but not limited to, a balance sheet and profit and loss statement and
any other report requested by Bank relating to the Collateral and the financial
condition of Borrower, and a certificate signed by an authorized employee of
Borrower to the effect that all reports, statements, computer disk or tape
files, computer printouts, computer runs, or other computer prepared
information of any kind or nature relating to the foregoing or documents
delivered or caused to be delivered to Bank under this subparagraph are
complete, correct and thoroughly present the financial condition of borrower
and that there exists on the date of delivery to Bank no condition or event
which constitutes a breach or Event of Default under this Agreement.
<PAGE>   17

Section 6.16(c) is amended by adding the following schedules:

        Monthly Accounts Receivable and Accounts Payable agings of JMAR
Precision systems on a monthly basis.

        Quarterly Accounts Receivable and Accounts Payable agings of JMAR
Semiconductor and JMAR Research.

/s/ DENNIS E. VALENTINE
--------------------------------------
JMAR Technologies

<PAGE>   18

[COMERICA LOGO]

                                INVENTORY RIDER
                              (REVOLVING ADVANCE)

BORROWER(S): JMAR Technologies, Inc.

     Borrower has entered into a certain Revolving Credit and Security
Agreement (Accounts and Inventory) or a certain Loan and Security Agreement
(Accounts and Inventory) (either hereinafter referred to as "Agreement") dated
December 20, 1999 with Bank (Secured Party). This INVENTORY RIDER (hereinafter
referred to as this Rider) dated December 20, 1999 is hereby made a part of and
incorporated into that agreement.

     1. At the request of Borrower, made at any time and from time to time
during the term of the Agreement, and so long as no event of default under the
Agreement has occurred and Borrower is in full, faithful and timely compliance
with each and all of the covenants, conditions, warranties and representations
contained in the Agreement, this Rider and/or any other agreement between Bank
and Borrower, Bank agrees to lend Borrower Thirty Five Percent (35.000%) of the
lower of cost or market value of Borrower's raw materials and finished goods
Inventory, and as may be adjusted by Bank, in Bank's discretion, for age and
seasonality or other factors affecting the value of the Inventory, up to a
maximum advance outstanding at any one time of Two Million Five Hundred
Thousand and no/100 Dollars ($2,500,000.00) upon Borrower's concurrent
execution and delivery to Bank of a Designation of Inventory, or Certification
of Borrowing Base, in form customarily used by Bank. All advances made and to
be made pursuant to this Rider are solely and exclusively to enable Borrower to
acquire rights in and purchase new Inventory, and Borrower represents and
warrants that all advances by Bank pursuant to this Rider will be used solely
and exclusively for such purpose; and since such advances will be used for the
foregoing purposes, Bank's security interest in Borrower's Inventory is and
shall be at all times a purchase money security interest as that term is
described in Section 9107 of the California Uniform Commercial Code.

     2. Advances made by Bank to Borrower pursuant to this Rider shall be
included as part of the Obligations of Borrower to Bank as the term
"Obligations" is defined in the Agreement; and at Bank's option, advances
pursuant to this Rider may be evidenced by promissory note(s), in form and on
terms satisfactory to Bank. All such advances shall bear interest at the rate
and be payable in the manner specified in said promissory note(s) in the event
Bank exercises the aforementioned option, and in the event Bank does not, such
advances shall bear interest at the rate and be payable in the manner specified
in the Agreement.

     3. All of the terms, covenants, warranties, conditions, agreements and
representations of the Agreement are incorporated herein as though set forth in
their entirety and are hereby reaffirmed by Borrower and Bank as though fully
set forth herein.

BORROWER(S): JMAR Technologies, Inc.

/s/ DENNIS E. VALENTINE
--------------------------------        -----------------------------------
By:                                     By:

--------------------------------        -----------------------------------
By:                                     By:

Accepted this 20th day of December, 1999 at Bank's place of business in San
Jose, CA 95113.

                                        /s/ BROCK MULLINS
                                        -----------------------------------
                                        By: Brock Mullins, Vice President

<PAGE>   19

                Addendum to Inventory Rider (Revolving Advance)
                            Dated December 30, 1999

Section 1 is hereby amended as follows:

        1. At the request of Borrower, made at any time and from time to time
during the term of the Agreement, and so long as no event of default under the
Agreement has occurred and Borrower is in full, faithful and timely compliance
with each and all of the covenants, conditions, warranties and representations
contained in the Agreement, this Rider and/or any other agreement between Bank
and Borrower, Bank agrees to lend Borrower Thirty Five Percent (35.00%) of the
lower of cost or market value of JMAR Precision Systems' total inventory, and as
may be . . .

/s/ DENNIS E. VALENTINE
-------------------------------
JMAR Technologies<PAGE>   1

                                                                   EXHIBIT 10.58

*_______* Indicates that material has been omitted and confidential treatment
 has been requested therefor. All such omitted material has been filed
 separately with the Secretary of Commission in the Company's Application
 Requesting Confidential Treatment pursuant to Rule 24b-2 under the Securities
 Exchange Act of 1934, as amended.

                   AMENDED AND RESTATED COLLABORATIVE RESEARCH
                              AND LICENSE AGREEMENT

                                     BETWEEN

                        IDEC PHARMACEUTICALS CORPORATION

                                       AND

                            SMITHKLINE BEECHAM P.L.C.

<PAGE>   2

                   AMENDED AND RESTATED COLLABORATIVE RESEARCH
                              AND LICENSE AGREEMENT
          IDEC PHARMACEUTICALS CORPORATION---SMITHKLINE BEECHAM P.L.C.

<TABLE>
<CAPTION>
                                TABLE OF CONTENTS
                                                                                           Page
<S>                                                                                         <C>
1.   DEFINITIONS.............................................................................4

2.   LICENSE GRANT...........................................................................7

3.   SUPPLY OF COMPOUND AND RELATED KNOW-HOW AND STUDIES.....................................7

4.   DEVELOPMENT AND COMMERCIALIZATION RIGHTS................................................9

5.   ROYALTIES..............................................................................10

6.   TERM, TERMINATION AND RIGHTS ON TERMINATION............................................11

7.   EXCHANGE OF INFORMATION AND CONFIDENTIALITY............................................12

8.   PATENT PROSECUTION.....................................................................12

9.   PATENT LITIGATION......................................................................13

10.  STATEMENTS AND REMITTANCES; AUDIT......................................................15

11.  WARRANTIES, REPRESENTATIONS, INSURANCE AND INDEMNIFICATIONS............................15

12.  FORCE MAJEURE..........................................................................17

13.  GOVERNING LAW..........................................................................18

14.  ARBITRATION............................................................................18

15.  SEPARABILITY...........................................................................18

16.  ENTIRE AGREEMENT.......................................................................18

17.  NOTICES................................................................................18

18.  RECORDATION............................................................................19

19.  ASSIGNMENT.............................................................................19

20.  EXECUTION IN COUNTERPARTS..............................................................19
</TABLE>

                                                                               2
<PAGE>   3

                       AMENDED AND RESTATED COLLABORATIVE
                         RESEARCH AND LICENSE AGREEMENT

        THIS AMENDED AND RESTATED COLLABORATIVE RESEARCH AND LICENSE AGREEMENT
(hereinafter the "AGREEMENT"), made as of the 29th day of February, 2000,
between SmithKline Beecham p.l.c., a company organized under English law and
having its registered office at New Horizons Court, Brentford, Middlesex TW8
9EP, England (hereinafter "SB") and IDEC Pharmaceuticals Corporation, a company
organized under the laws of the State of Delaware and having its principal
executive offices at 3020 Callan Road, San Diego, California 92121 (hereinafter
"IDEC").

                                WITNESSETH THAT:

        WHEREAS, SB AND IDEC entered into a Collaborative Research and License
AGREEMENT dated October 12, 1992 as amended by: (i) an extension of Negotiation
Period executed January 15, 1993 by SB; (ii) an Amendment Agreement dated
January 20, 1993; (iii) an Amendment Agreement to the January 20, 1993 Amendment
Agreement dated January 27, 1993; (iv) an Amendment Agreement to the January 20,
1993 Amendment Agreement dated June 14, 1993; (v) a letter dated August 9, 1993;
(vi) an Amendment Agreement dated May 26, 1994; and (vii) an Amendment Agreement
dated February 1, 2000 (the "February 2000 Amendment")(collectively, the
"Original Agreement");

        WHEREAS, pursuant to the Original Agreement, IDEC granted SB worldwide
licenses under certain patents, patent applications and know-how relating to
products directed against the CD4+ cell function and the use of such products
for the palliation, treatment and/or prophylaxis of disease states which are
caused or exacerbated by cells expressing the CD4+ determinant;

        WHEREAS, pursuant to the February 2000 Amendment, the parties have
terminated (i) their collaboration for the development and commercialization of
products and (ii) all licenses granted to SB under the Original Agreement with
full reversion to IDEC of all IDEC's interest and rights in patent rights and
know-how subject to such licenses;

        WHEREAS, also pursuant to the February 2000 Amendment, SB granted to
IDEC worldwide licenses under any and all patents, patent applications and
know-how owned or controlled by SB covering the making, use, importation, offer
or sale of COMPOUND (as defined in the Original Agreement) other than patents,
patent applications and know-how related to SB proprietary manufacturing or
formulation information, and SB further agreed to provide certain limited
technical assistance to IDEC in connection therewith;

        WHEREAS, SB and IDEC desire to restate their respective rights and
obligations as currently set forth in the Original Agreement, as amended, and to
replace the Original Agreement with this AGREEMENT;

                                                                               3
<PAGE>   4

        NOW, THEREFORE, in consideration of the covenants and obligations
expressed herein, and intending to be legally bound, and otherwise to be bound
by proper and reasonable conduct, the parties agree as follows:

1.      DEFINITIONS

        1.1 "AFFILIATES" shall mean any corporation, firm, partnership or other
entity, whether de jure or de facto, which directly or indirectly owns, is owned
by or is under common ownership with a party to this AGREEMENT to the extent of
at least fifty percent (50%) of the equity (or such lesser percentage which is
the maximum allowed to be owned by a foreign corporation in a particular
jurisdiction) having the power to vote on or direct the affairs of the entity
and any person, firm, partnership, corporation or other entity actually
controlled by, controlling or under common control with a party to this
AGREEMENT.

        1.2 "AT IDEC's EXPENSE" shall mean that IDEC shall pay all reasonable
FTE COSTS, materials, supplies and out-of-pocket expenses incurred by SB, its
agents, contractors and consultants, in executing SB's obligations to IDEC under
this AGREEMENT, including all costs and expenses incurred by SB for stability
testing and regulatory activities commenced by SB under Section 3 after February
2, 2000.

        1.3 "CLENOLIXIMAB" shall mean the form of COMPOUND developed by SB and
IDEC pursuant to the Original Agreement.

        1.4 "COMMERCIAL SALE" shall mean the first sale of COMPOUND to a THIRD
PARTY purchaser in an IDEC COUNTRY after receipt of all regulatory approvals
necessary to sell COMPOUND. Such approval in Europe shall include any requisite
pricing and reimbursement approvals in conjunction with the Marketing
Authorization Application for COMPOUND in at least one (1) MAJOR EUROPEAN
COUNTRY.

        1.5 "COMPOUND" shall mean any composition of matter, the intellectual
property rights to which are owned in whole or in part by IDEC or licensed to
IDEC under Section 2, which is directed against the CD4+ determinant, such as,
but not limited to, the human/Old World monkey chimeric antibodies known as
CE9.1 and G4PE50 (CLENOLIXIMAB), which selectively binds to and/or regulates the
functions of CD4+ cells and/or the immune system.

        1.6 "DEVELOPMENT" shall mean preclinical and clinical research on a
COMPOUND conducted primarily with the intent, and for the purpose, of generating
data for submission to a regulatory authority in any of the GEOGRAPHIES in
support of an application for governmental approval required for commercializing
COMPOUND for any indication.

        1.7 "EFFECTIVE DATE" shall mean the date as of which this AGREEMENT is
effective and shall be the date of this AGREEMENT first written above.

        1.8 "EUROPE" shall mean all countries that are Member States of the
European Union as of the EFFECTIVE DATE.

        1.9 "FDA" shall mean the United States Food and Drug Administration.

                                                                               4
<PAGE>   5

        1.10 "FTE COSTS" shall apply to either (i) an SB employee who is a
full-time equivalent professional employee of SB, other than a clerical,
administrative assistant, or secretarial employee or (ii) an SB employee who
does not fit within the scope of Section 1.10(i). SB employees within the scope
of Section 1.10(i) shall be chargeable to IDEC at an hourly rate based on an FTE
rate of *_________________ * per annum. SB employees within the scope of Section
1.10(ii) shall be chargeable to IDEC at an hourly rate based on an FTE rate of
*___________________* per annum.

        1.11 "GEOGRAPHY(IES)" shall mean, depending on context, the U.S.A.,
EUROPE, and/or the R.O.W.

        1.12 "IND" shall mean an Investigational New Drug Application filed with
the FDA.

        1.13 "IDEC" shall mean IDEC Pharmaceuticals Corporation, its AFFILIATES,
successors and permitted assigns.

        1.14 "IDEC COUNTRY(IES)" shall mean those countries of the world for
which SB has no rights to develop and commercialize COMPOUND pursuant to
Sections 4.3 and 4.4 of this AGREEMENT.

        1.15 "IDEC NET SALES" shall mean the gross receipts from sales of
COMPOUND in the IDEC COUNTRY(IES) by IDEC, its AFFILIATES and its licensees to
THIRD PARTIES, less deductions for: (i) transportation charges, including
insurance; (ii) sales and excise taxes and duties paid or allowed by a selling
party and any other governmental charges imposed upon the production,
importation, use or sale of such COMPOUND; (iii) normal and customary trade,
quantity and cash discounts allowed and actually taken; and (iv) allowances or
credits to customers on account of rejection or return of COMPOUND, subject to
the royalty provisions under this AGREEMENT. Sales between or among IDEC and its
AFFILIATES and its or their sublicensees shall be excluded from the computation
of IDEC NET SALES except where such AFFILIATES or sublicensees are end users,
but IDEC NET SALES shall include the subsequent final sales to THIRD PARTIES by
such AFFILIATES or sublicensees.

        1.16 "MAJOR EUROPEAN COUNTRY(IES)" shall mean the United Kingdom,
France, Germany, Italy or Spain.

        1.17 "NDA" shall mean a New Drug Application in accordance with the
requirements of the FDA.

        1.18 "OPT IN" shall mean SB's exclusive, nontransferable (other than as
provided in Section 19) option to negotiate, for a period of *_____________*
right with IDEC to co-develop and co-commercialize COMPOUND with IDEC in the
*_________________,* as provided in Sections 4.2 and 4.3.

        1.19 "R.O.W." shall mean all the countries of the world except for the
U.S.A. and EUROPE.

        1.20 "SB" shall mean SmithKline Beecham p.l.c., its AFFILIATES,
successors and permitted assigns.

*_______* Indicates that material has been omitted and confidential treatment
 has been requested therefor. All such omitted material has been filed
 separately with the Secretary of Commission in the Company's Application
 Requesting Confidential Treatment pursuant to Rule 24b-2 under the Securities
 Exchange Act of 1934, as amended.

                                                                               5
<PAGE>   6

        1.21 "SB KNOW-HOW" shall mean all information and know-how which relates
to COMPOUND and shall include, without limitation, all chemical,
pharmacological, toxicological, clinical, and assay information, and any other
information relating to COMPOUND and useful or required for the DEVELOPMENT and
commercialization of COMPOUND for any indication, which is known by SB as of the
EFFECTIVE DATE, to the extent that SB is free to disclose such as provided by
this AGREEMENT. "SB KNOW-HOW" shall not include *_______*

        1.22 "SB PATENTS" shall mean all patents and patent applications which
are owned by SB, or which SB otherwise has the right to grant licenses as of the
EFFECTIVE DATE, which generically or specifically claim COMPOUND, a process for
manufacturing COMPOUND, an intermediate used in such process, a method to
formulate or deliver COMPOUND or a use of COMPOUND. Included within the
definition of SB PATENTS are any continuations, continuations-in-part,
divisions, patents of addition, reissues, renewals or extensions thereof. The
current list of patent applications and patents encompassed within SB PATENTS,
if any, is set forth in APPENDIX A attached hereto and incorporated herein.

        1.23 "STUDY *_________*" shall mean the clinical study whose protocol is
described in Exhibit I to this AGREEMENT, attached hereto and incorporated
herein.

        1.24 "THIRD PARTY(IES)" shall mean any party other than SB, IDEC or
their respective AFFILIATES.

        1.25 "THIRD PARTY KNOW-HOW" shall mean all information and know-how
which relates to COMPOUND and shall include, without limitation, all chemical,
pharmacological, toxicological, clinical, assay, control and manufacturing data
and any other information and shall include, without limitation, all chemical,
pharmacological, clinical, assay, control and manufacturing data and any other
information and reagents relating to COMPOUND and useful or required for the
DEVELOPMENT and commercialization of COMPOUND for any indication owned by a
THIRD PARTY which is controlled by SB or which SB otherwise has the right to
disclose or grant licenses as of the EFFECTIVE DATE.

        1.26 "THIRD PARTY PATENTS" shall mean all patents and patent
applications which are owned by a THIRD PARTY but controlled by SB or which SB
otherwise has the right to grant licenses as of the EFFECTIVE DATE, which
generically or specifically claim COMPOUND. Included within the definition of
THIRD PARTY PATENTS are any continuations, continuations-in-part, divisions,
patents of addition, reissues, renewals or extensions thereof. The current list
of patent applications and patents encompassed within THIRD PARTY PATENTS (if
any) is set forth in APPENDIX A attached hereto and incorporated herein.

        1.27 "U.S.A." shall mean the United States of America, and its
territories and possessions.

*_______* Indicates that material has been omitted and confidential treatment
 has been requested therefor. All such omitted material has been filed
 separately with the Secretary of Commission in the Company's Application
 Requesting Confidential Treatment pursuant to Rule 24b-2 under the Securities
 Exchange Act of 1934, as amended.

                                                                               6
<PAGE>   7

2.      LICENSE GRANT

        2.1 SB hereby grants to IDEC an exclusive license, with the right to
grant sublicenses under SB PATENTS and SB KNOW-HOW to make, have made, use,
import, offer for sale, and sell COMPOUND in any country or territory of the
world; provided that such license shall not extend to the
*_____________________________________,* except as otherwise provided in this
AGREEMENT and subject to SB's obligations to *______________________* as
provided in this AGREEMENT. It is agreed and understood that SB retains its
interests and rights in such SB PATENTS and SB KNOW-HOW for all other purposes,
including, without limitation, the right to grant similar licenses under such SB
PATENTS and SB KNOW-HOW to THIRD PARTIES, but only to the extent that such SB
PATENTS and SB KNOW-HOW cover the making, use, import, offer of sale, or sale of
anything other than COMPOUND in any country of the world.

        2.2 SB hereby grants to IDEC an exclusive license, with the right to
grant sublicenses under THIRD PARTY PATENTS and THIRD PARTY KNOW-HOW to make,
have made, use, import, offer for sale, and sell COMPOUND in any country or
territory in the world; provided that such license shall not extend to the use
of *__________________________,* except as otherwise provided in this AGREEMENT.
It is agreed and understood that SB retains its interests and rights in such
THIRD PARTY PATENTS and THIRD PARTY KNOW-HOW for all other purposes, including,
without limitation, the right to grant similar licenses under such THIRD PARTY
PATENTS and THIRD PARTY KNOW-HOW to THIRD PARTIES, but only to the extent that
such THIRD PARTY PATENTS and THIRD PARTY KNOW-HOW cover the making, use, import,
offer of sale, or sale of anything other than COMPOUND in any country of the
world. SB shall not take any action to terminate any licenses under THIRD PARTY
PATENTS and THIRD PARTY KNOW-HOW without IDEC's prior written consent.

        2.3 Upon IDEC's request and for no additional consideration to SB, SB
shall grant IDEC a sublicense for the making, importing, use and/or sale of
COMPOUND in any country or territory in the world under SB's non-exclusive
license rights to make, have made, use, import, offer for sale or sell COMPOUND
as provided *_____________________________* In addition, within five (5) days
after *_______________________*

3.      SUPPLY OF COMPOUND AND RELATED KNOW-HOW AND STUDIES

        3.1 If not already done, SB will:

            (a) transfer those components of SB's current IND related to the
manufacture of CLENOLIXIMAB as soon as practicable after the EFFECTIVE DATE to a
Drug Master File ("DMF"), AT IDEC's EXPENSE;

            (b) provide IDEC with the right to cross-reference the DMF;
provided, however, IDEC may not access such DMF;

            (c) make available to IDEC, upon request and within a reasonable
time period, a list of pre-clinical and clinical reports not related to COMPOUND
manufacture, but including any pre-clinical and clinical comparability reports,
that have been or will be submitted to SB's IND for CLENOLIXIMAB. Within thirty
(30) days after receipt of such list, IDEC will

*_______* Indicates that material has been omitted and confidential treatment
 has been requested therefor. All such omitted material has been filed
 separately with the Secretary of Commission in the Company's Application
 Requesting Confidential Treatment pursuant to Rule 24b-2 under the Securities
 Exchange Act of 1934, as amended.

                                                                               7
<PAGE>   8

identify to SB, in writing, those reports which they require from SB to submit
to IDEC's IND for COMPOUND. AT IDEC's EXPENSE, SB will provide IDEC a copy of
the indicated reports. Such reports will be provided to IDEC in electronic form
to the extent available; otherwise they will be provided to IDEC in written
form. In the event that SB closes its IND for CLENOLIXIMAB, SB will give IDEC
prior notification thereof.

        3.2 At IDEC's request, SB will provide IDEC with a copy of any existing
clinical databases related to COMPOUND that IDEC reasonably requires to support
its NDA for COMPOUND, AT IDEC's EXPENSE. Such databases will be provided to IDEC
in electronic form to the extent available, otherwise they will be provided to
IDEC in written form. Such delivery will take place as soon as practicable.

        3.3 The following shall be applicable to SB's obligation to supply
CLENOLIXIMAB and reagents to IDEC or its designate under this AGREEMENT:

            (a) If not already done, before *__________,* SB will initiate
stability testing on existing batches of CLENOLIXIMAB to obtain approximately
*________* vials of CLENOLIXIMAB *____________________* At such time as when the
testing has been completed and *__________________________,* SB shall ship the
vials to IDEC or its designate, and the vials shall become the property of IDEC
as soon as such supplies are in the charge of IDEC's designated carrier. IDEC
shall bear all of SB's costs related to the storage and stability testing of
such supplies *________________*

            (b) For each product lot shipped to IDEC, SB will provide IDEC with
the following:

                (i) Batch Documentation for each product lot;

                (ii) Certificates of Analysis for each product lot;

                (iii) Certificate of Compliance for each product lot; and

                (iv) Stability reports for each product lot.

            Each Certificate of Compliance will read: "SB certifies that the
referenced product lot was produced in compliance to applicable cGMPs with
respect to its materials, processes, procedures and analyses. The method of
manufacture and quality assurance/quality control of the drug substance and drug
product are consistent with that described in the filed DMF. SB certifies that
the reference product lot is not adulterated within the meaning of the Federal
Food, Drug, and Cosmetic Act. SB further certifies that the referenced product
lot is safe, potent and pure from a manufacturing perspective."

            (c) SB warrants and represents that all such supplies of
CLENOLIXIMAB meet specifications as set forth in Section 3.3(b), and have been
kept under GMP and will continue to be kept under GMP by SB until such supplies
are in the charge of IDEC's designated carrier. IDEC shall select the carrier
for shipping of all such supplies and IDEC shall bear all costs associated with
the shipping of such supplies to IDEC. SB warrants and represents that stability
work will be conducted on such existing supplies of CLENOLIXIMAB in accordance
with FDA regulations.

*_______* Indicates that material has been omitted and confidential treatment
 has been requested therefor. All such omitted material has been filed
 separately with the Secretary of Commission in the Company's Application
 Requesting Confidential Treatment pursuant to Rule 24b-2 under the Securities
 Exchange Act of 1934, as amended.

                                                                               8
<PAGE>   9

            (d) At the same time that SB is shipping the supplies outlined in
Section 3.3(a), SB shall ship, at IDEC'S EXPENSE, the reagents/standards and
test procedures necessary to enable IDEC to carry out further stability testing
on such supplies and to perform the identity test after labeling.

            (e) SB's DMF will cover manufacture of bulk drug substance as well
as unlabeled product lots shipped to IDEC.

        3.4 IDEC acknowledges that, due to the period of time which has elapsed
since SB conducted clinical trials with COMPOUND and last manufactured COMPOUND,
the knowledge of SB with respect to preclinical and clinical information,
clinical trial databases/programming information, and manufacturing process
information, and all other information or data related to COMPOUND is not
current and, in some cases, key personnel have either left SB or moved to
different roles within SB and may not be available. IDEC further acknowledges
that all COMPOUND, information and assistance provided to IDEC under this
AGREEMENT *_______________________________________* Subject to the foregoing, SB
will attempt to provide a reasonable response to IDEC's reasonable inquires
related to the information transferred to IDEC pursuant to this AGREEMENT within
a reasonable time frame, and shall attempt to respond to FDA directly for
chemistry, manufacturing and controls ("CMC") questions, if any, asked by the
FDA, AT IDEC's EXPENSE, but only to the extent that SB has the available
resources and expertise to do so. SB shall be under no obligation to provide
substantive resources or maintain appropriate expertise for this effort or to
assist IDEC in the development of COMPOUND in any way. Notwithstanding the
foregoing, SB shall perform its obligations under this Section 3 with the same
effort that it would apply to its own compound with similar regulatory
requirements and market potential.

        3.5 SB will have no obligation to provide IDEC with *________________*

        3.6 *____________________________*

        3.7 SB disclaims any and all implied warranties that COMPOUND provided
to IDEC under this AGREEMENT has been tested or will meet applicable
specifications except as otherwise expressly stated in this AGREEMENT. SB
disclaims any and all implied warranties that the information SB provided to
IDEC under this AGREEMENT is necessary or appropriate for FDA or other
regulatory or governmental agency review of COMPOUND except as otherwise
expressly stated in this AGREEMENT. Finally, with respect to COMPOUND,
information, and assistance provided to IDEC under this AGREEMENT, SB disclaims
any warranties or representations, either express or implied, whether in fact or
in law, including without limitation implied warranties of merchantability or
fitness for a particular purpose or noninfringement, except as otherwise
expressly stated in this AGREEMENT.

        3.8 In consideration of execution of this AGREEMENT and the payment by
SB to IDEC of the amount of *_______________________* by March 3, 2000, SB's
obligations under Paragraph 13.01 of the Original Agreement shall be deemed
fulfilled.

4.      DEVELOPMENT AND COMMERCIALIZATION RIGHTS

        4.1 Subject to Section 4.2, IDEC will have full scientific and
management authority and control in connection with the DEVELOPMENT of COMPOUND
under IDEC's IND;

*_______* Indicates that material has been omitted and confidential treatment
 has been requested therefor. All such omitted material has been filed
 separately with the Secretary of Commission in the Company's Application
 Requesting Confidential Treatment pursuant to Rule 24b-2 under the Securities
 Exchange Act of 1934, as amended.

                                                                               9
<PAGE>   10

provided that it is understood that IDEC's initial efforts at such continued
DEVELOPMENT shall be directed *___________________________* IDEC shall also have
full responsibility for the attainment and maintenance of regulatory approvals
and price registrations for COMPOUND in all GEOGRAPHIES in the world.

        Notwithstanding the foregoing, the parties acknowledge that IDEC shall
have no obligation to continue DEVELOPMENT of COMPOUND. Subject to this Section
and Section 4.2, IDEC shall have the sole authority and control over DEVELOPMENT
and commercialization of COMPOUND in whatever form, including without
limitation, preclinical and clinical research, submissions of applications to
regulatory authorities in pursuit of approvals in a country for making,
importing, distributing and selling a product and the development and
implementation of marketing plans for COMPOUND.

        4.2 At such time as *___________________________* SB shall have the OPT
IN and shall notify IDEC of its intent to exercise the OPT IN in writing no
later than thirty (30) days following SB's receipt of the headline data.

        4.3 In the event that SB exercises the OPT IN, SB will have the
exclusive right to negotiate (for a period of *________________* following
SB's notice to IDEC of its exercise of the OPT IN) a mutually acceptable
agreement with IDEC related to such co-development/co-commercialization of
COMPOUND (a "Co-Development/Co-Commercialization Agreement") in the elected
GEOGRAPHIES. The Co-Development/Co-Commercialization Agreement may provide that
for each GEOGRAPHY, *_____________________* Notwithstanding the foregoing, SB
will have no obligation to exercise the OPT IN *_______________*

        4.4 In the event that SB exercises the OPT IN for *_________________,*
but SB and IDEC are unable to reach mutually acceptable terms during the
*___________* period for the elected GEOGRAPHY(IES), *)________________*

        4.5    *_____________________*

5.      ROYALTIES

        5.1 In consideration of the license grant to IDEC under Section 2, IDEC
shall pay SB the following royalties:

            (a) if commercial supply of COMPOUND utilizes SB's proprietary cell
line expressing COMPOUND, then in consideration for such use of the cell line
together with SB's provision of the information, supplies and assistance to IDEC
under Section 3 of this AGREEMENT, IDEC shall pay SB the following royalties:

                (i) *____________* of annual IDEC NET SALES up to and including
*___________________*

                (ii) *___________* of annual IDEC NET SALES greater than
*_____________________*

*_______* Indicates that material has been omitted and confidential treatment
 has been requested therefor. All such omitted material has been filed
 separately with the Secretary of Commission in the Company's Application
 Requesting Confidential Treatment pursuant to Rule 24b-2 under the Securities
 Exchange Act of 1934, as amended.

                                                                              10
<PAGE>   11

            (b) if commercial supply of COMPOUND does not utilize SB's
proprietary cell line expressing COMPOUND, then IDEC shall pay SB
*_______________* of annual IDEC NET SALES.

        5.2 IDEC's royalty obligations for COMPOUND under Section 5.1 shall
commence in each IDEC COUNTRY upon the COMMERCIAL SALE of COMPOUND in such
country and shall expire: (a) in the U.S.A., *__________________ * (b) in
EUROPE, upon the expiration of *__________________* and (c) in the R.O.W., upon
the expiration of *_______________ * Expiration of IDEC's royalty obligations
and payment obligations related to COMPOUND under this provision shall not
preclude IDEC from continuing to market COMPOUND and to use SB PATENTS, SB
KNOW-HOW, THIRD PARTY PATENTS, THIRD PARTY KNOW-HOW and other sublicensed rights
in the relevant GEOGRAPHY without further royalty payments or any other payments
to SB.

6.      TERM, TERMINATION AND RIGHTS ON TERMINATION

        6.1 Unless otherwise terminated, this AGREEMENT shall expire
*___________________* Expiration of this AGREEMENT under this provision shall
not preclude IDEC from continuing to market any COMPOUND and to use SB PATENTS,
SB KNOW-HOW, THIRD PARTY PATENTS and THIRD PARTY KNOW-HOW and other sublicensed
rights anywhere in the world without further royalty payments.

        6.2 If SB materially fails or neglects to perform its respective
obligations set forth in this AGREEMENT and if such default is not corrected
within sixty (60) days after receiving written notice from IDEC with respect to
such default, IDEC shall have the right to terminate SB's rights under Sections
4 and 5 by giving written notice to SB. If IDEC materially fails or neglects to
perform its respective obligations set forth in this AGREEMENT and if such
default is not corrected within sixty (60) days after receiving written notice
from SB with respect to such default, SB shall have the right to terminate
IDEC's rights under Sections 2 and 3 by giving written notice to IDEC.

        6.3 Either party may terminate this AGREEMENT if, at any time, the other
party shall file in any court or agency pursuant to any statute or regulation of
any state or country, a petition in bankruptcy or insolvency or for
reorganization or for an arrangement or for the appointment of a receiver or
trustee of the party or of its assets, or if the other party proposes a written
AGREEMENT of composition or extension of its debts, or if the other party shall
be served with an involuntary petition against it, filed in any insolvency
proceeding, and such petition shall not be dismissed within sixty (60) days
after the filing thereof, or if the other party shall propose or be a party to
any dissolution or liquidation, or if the other party shall make an assignment
for the benefit of creditors. Notwithstanding the bankruptcy of SB, IDEC shall
be entitled to retain the licenses granted herein, and subject to performance by
IDEC of its preexisting obligations under this AGREEMENT.

        6.4 Termination of this AGREEMENT shall terminate all outstanding
obligations and rights between the parties arising from this AGREEMENT, except
those described in Sections 2, 5, 7, 8, 9, 10, 11, 13, 14, 15, 16, 17, 18 and 19
and any existing rights of one party against the other party for a breach by
that party.

*_______* Indicates that material has been omitted and confidential treatment
 has been requested therefor. All such omitted material has been filed
 separately with the Secretary of Commission in the Company's Application
 Requesting Confidential Treatment pursuant to Rule 24b-2 under the Securities
 Exchange Act of 1934, as amended.

                                                                              11
<PAGE>   12

        6.5 All rights to terminate, and rights upon termination, provided for
either party in this AGREEMENT are in addition to other remedies in law or
equity which may be available to either party.

7.      EXCHANGE OF INFORMATION AND CONFIDENTIALITY

        7.1 During the term of this AGREEMENT, SB shall promptly disclose to
IDEC and/or supply IDEC with SB KNOW-HOW and THIRD PARTY KNOW-HOW which SB owns
or controls as of the EFFECTIVE DATE; provided SB shall not be under any
obligation to disclose any SB proprietary manufacturing or formulation
information for the making, use or sale of COMPOUND except as otherwise provided
in this AGREEMENT.

        7.2 Neither party, during the term of this AGREEMENT and for a period of
five (5) years after the date of termination of this AGREEMENT, shall disclose
or reveal to THIRD PARTIES any confidential information received from the other
party or otherwise developed by either party in the performance of activities in
furtherance of this AGREEMENT or the Original Agreement which relates
substantially to a COMPOUND. This confidentiality obligation shall not apply to
such information which is or becomes a matter of public knowledge, or came or
comes into the possession of the receiving party independently of this
AGREEMENT, or is disclosed to the receiving party by a THIRD PARTY having the
right to do so, or is subsequently and independently developed by employees of
the receiving party or AFFILIATES thereof who had no knowledge of the
confidential information disclosed. The parties shall take reasonable measures
to ensure that no unauthorized use or disclosure is made by others to whom
access to such information is granted. Notwithstanding the foregoing, IDEC shall
be entitled to use, reveal and disclose with and to THIRD PARTIES any
confidential information received from SB which relates to a COMPOUND whether
received pursuant to the AGREEMENT or the Original Agreement without first
obtaining the written consent of SB.

        7.3 No public announcement or other disclosure to THIRD PARTIES
concerning the existence of or terms of this AGREEMENT shall be made, either
directly or indirectly, by either party to this AGREEMENT, except as may be
legally required or as may be required for recording purposes, without first
obtaining the written approval of the other party and AGREEMENT upon the nature
and text of such announcement or disclosure; provided that such approval shall
not be unreasonably withheld. The party desiring to make any such public
announcement or other disclosure shall use reasonable efforts to inform the
other party of the proposed announcement or disclosure in reasonably sufficient
time prior to public release, and shall use reasonable efforts to provide the
other party with a written copy thereof, in order to allow such other party to
comment upon such announcement or disclosure.

        7.4 Nothing in this AGREEMENT shall be construed as preventing or in any
way inhibiting IDEC or SB from complying with statutory and regulatory
requirements governing the manufacture, use and sale or other distribution of
COMPOUND in any country in the world in any manner it reasonably deems
appropriate, including, for example, by disclosing to regulatory authorities
confidential or other information received from the other or THIRD PARTIES.

8.      PATENT PROSECUTION

        8.1 SB shall disclose to IDEC the complete texts of all SB PATENTS and
THIRD PARTY PATENTS (if any) filed by SB prior to the EFFECTIVE DATE which
relate to

                                                                              12
<PAGE>   13

COMPOUND as well as all information received concerning the institution or
possible institution of any interference, opposition, re-examination, reissue,
revocation, nullification or any official proceeding involving such patents
anywhere in the world.

        8.2 SB shall prepare, file, prosecute, maintain, extend and defend
patent applications and issued patents included in the licenses granted pursuant
to Section 2 so as to protect the commercial interests of the parties in
COMPOUND in the U.S., Europe and such other countries where patent applications
and issued patents exist as of the EFFECTIVE DATE. SB shall not abandon any such
patent applications in any country without IDEC's written consent. SB shall
promptly advise IDEC of the grant, lapse, revocation, surrender, invalidation,
or abandonment of any patents subject to Section 2 anywhere in the world.
Notwithstanding the foregoing, IDEC shall have the right to assume
responsibility for the preparation, filing, prosecution, maintenance and defense
of any a patent or patent application or any part thereof in any country for
which SB has the right to prosecute and maintain; provided that the claims of
such patents covers COMPOUND. IDEC acknowledges that all right, title and
interest in and to the SB PATENTS in and to the SB PATENTS are and shall remain
in SB, subject to the express license rights granted to IDEC under Section 2 of
this AGREEMENT.

9.      PATENT LITIGATION

        9.1 In the event of the institution of any suit by a THIRD PARTY against
IDEC, SB and/or its sublicensees for patent infringement involving an SB PATENT
or THIRD PARTY PATENT subject to Section 2 anywhere in the world, the party sued
shall promptly notify the other party in writing. IDEC shall have the right but
not the obligation to defend such suit at its own expense. IDEC and SB shall
assist one another and cooperate in any such litigation at the other's request
without expense to the requesting party.

        9.2 In the event that IDEC or SB becomes aware of actual or threatened
infringement of an SB PATENT or THIRD PARTY PATENT subject to Section 2 anywhere
in the world, that party shall promptly notify the other party in writing. IDEC
shall have the first right but not the obligation to bring, at its own expense,
an infringement action or file any other appropriate action or claim directly
related to infringement of a patent or patent application subject to Section 2
wherein such infringement relates to COMPOUND, against any THIRD PARTY and to
use SB's name in connection therewith. If IDEC does not commence a particular
infringement action within ninety (90) days after it received such written
notice, SB, after notifying IDEC in writing, shall be entitled to bring such
infringement action or any other appropriate action or claim at its own expense.
The party conducting such action shall have full control over its conduct. In
any event, IDEC and SB shall assist one another and cooperate in any such
litigation at the other's request without expense to the requesting party.

        9.3 IDEC and SB shall recover their respective actual out-of-pocket
expenses, or equitable proportions thereof, associated with any litigation or
settlement thereof from any recovery made by any party. Any excess amount shall
be shared between SB and IDEC, with each party receiving an amount proportional
to the amount spent by such party on such litigation or settlement thereof
relative to the total amount spent by both parties on such litigation or
settlement thereof.

        9.4 The parties shall keep one another informed of the status of and of
their respective activities regarding any litigation or settlement thereof
concerning COMPOUND.

                                                                              13
<PAGE>   14

        9.5 SB shall authorize IDEC to act as SB's agent for the purpose of
making any application for any extensions of the term of SB PATENTS or THIRD
PARTY PATENTS of which SB is entitled to act as such an agent in any country in
the world in which such extensions are or become available, and shall provide
reasonable assistance therefor to IDEC, AT IDEC'S EXPENSE.

                                                                              14
<PAGE>   15

10.     STATEMENTS AND REMITTANCES; AUDIT

        10.1 IDEC shall pay all invoices received from SB within thirty (30)
days of receipt of such invoices.

        10.2 IDEC shall keep and require its AFFILIATES and sublicensees to keep
complete and accurate records of IDEC NET SALES. SB shall have the right, at
SB's expense, through a certified public accountant or like person reasonably
acceptable to IDEC, to examine such records during regular business hours during
the term of this AGREEMENT and for six (6) months after the later of its
termination or the last COMMERCIAL SALE of COMPOUND; provided, however, that
such examination shall not take place more often than once a year and shall not
cover such records for more than the preceding two (2) years; and provided
further that such accountant shall report to SB only as to the accuracy of the
IDEC NET SALES calculations, royalty statements and payments by IDEC to SB under
this AGREEMENT.

        10.3 Within sixty (60) days after the close of each calendar quarter
commencing with the first calendar quarter in which the COMMERCIAL SALE of a
COMPOUND occurs, IDEC shall deliver to SB a true accounting of IDEC NET SALES of
COMPOUND during such quarter and shall at the same time pay all royalties due to
SB under Section 5.1. Such accounting shall show IDEC NET SALES on a
country-by-country and COMPOUND-by-COMPOUND basis. Any tax paid or required to
be withheld by IDEC on account of royalties payable to SB under this AGREEMENT
shall be deducted from the amount of royalties otherwise due. IDEC shall secure
and send to SB written proof of any such taxes withheld and paid by IDEC or its
sublicensees for the benefit of SB in a form sufficient to satisfy the United
States Internal Revenue Service.

        10.4 All royalties due under this AGREEMENT shall be payable in U.S.
dollars. If governmental regulations in a country prevent remittances from IDEC
to SB in U.S. dollars with respect to IDEC NET SALES made in that country, SB
shall receive such royalty payment for IDEC NET SALES in that country in local
currency.

        10.5 Monetary conversions from the currency of a foreign country, in
which COMPOUND is sold, into United States currency shall be made at the average
daily rates of exchange for the year from January 1 to the end of such calendar
quarter, from such country's currency into U.S. Dollars as reported in the Wall
Street Journal or other source agreeable to both parties, and shall be converted
at such average year-to-date rate at the end of such quarter.

11.     WARRANTIES, REPRESENTATIONS, INSURANCE AND INDEMNIFICATIONS

        11.1 As of the EFFECTIVE DATE, SB warrants that, to the best of its
belief and knowledge, it owns the entire right and title to the extent of its
ownership interests in SB PATENTS and SB KNOW-HOW, or has the right to grant the
licenses outlined in Section 2.

        11.2 SB represents and warrants to IDEC that it has disclosed to IDEC:

            (a) any information that SB obtained or develops in any country of
the world regarding the utility or safety of COMPOUND (including CLENOLIXIMAB)
and any

                                                                              15
<PAGE>   16

confirmed information of serious or unexpected reactions or side effects related
to the utilization or medical administration of COMPOUND. "Serious" as used in
this Section refers to experience which results in death, permanent or
substantial disability, in-patient hospitalization, prolongation of existing
in-patient hospitalization; or is a congenital anomaly, cancer, the result of an
overdose or life threatening. "Unexpected" as used in this Section refers to (i)
conditions or developments encountered during preclinical or clinical studies
which could be material to the successful continuance of development of
COMPOUND; (ii) conditions or developments not encountered during clinical
studies of COMPOUND, and (iii) conditions or developments occurring with greater
frequency, severity, or specificity than shown by information previously
submitted to governmental agencies or encountered during clinical studies of
COMPOUND.

            (b) any information it has received regarding any threatened or
pending action by any regulatory agency in any country of the world which may
affect the safety or efficacy claims of COMPOUND or the continued marketing of
COMPOUND.

        11.3 Prior to or upon the first administration of COMPOUND to a human by
or on behalf of IDEC, and for a period of five (5) years after the expiration of
this AGREEMENT or its earlier termination, IDEC shall obtain and/or maintain,
respectively, at its sole cost and expense, product liability insurance in
amounts, respectively, which are reasonable and customary in the U.S.
pharmaceutical industry for companies of comparable size and activities.
*___________________________* Such product liability insurance shall insure
against all liability, including liability for personal injury, physical injury
and property damage. IDEC shall provide written proof of the existence of such
insurance to SB.

        11.4 IDEC shall indemnify and hold harmless SB, its officers, directors,
shareholders, employees, successors and assigns from any loss, damage, or
liability (including reasonable attorneys' fees) resulting from any claim,
complaint, suit, proceeding or cause of action against any of them alleging
physical or other injury, including death, brought by or on behalf of a THIRD
PARTY due to physical injury or death arising out of the administration,
utilization and/or ingestion of COMPOUND manufactured, sold or otherwise
provided to the THIRD PARTY by IDEC (or its permitted sublicensee), except to
the extent such damages, claims, costs, losses, liabilities or expenses are
directly and proximately caused by SB's negligent or wrongful actions and
provided:

            (a) IDEC shall not be obligated under this Section 11.5 if it is
shown by evidence acceptable in a court of law having jurisdiction over the
subject matter and meeting the appropriate degree of proof for such action, that
the injury was the result of the negligence or willful misconduct of any
employee or agent of SB;

            (b) IDEC shall have no obligation under this Section 11.5 unless SB
(i) gives IDEC prompt written notice of any claim or lawsuit or other action for
which it seeks to be indemnified under this AGREEMENT; (ii) IDEC is granted full
authority and control over the defense, including settlement, against such claim
or lawsuit or other action; and (iii) SB cooperates fully with IDEC and its
agents in defense of the claims or lawsuit or other action; and

            (c) The parties shall have an equal right to participate in the
defense of any such claim, complaint, suit, proceeding or cause of action
referred to in this Section utilizing attorneys of its choice; provided,
however, that IDEC shall have full authority and control to handle any such
claim, complaint, suit, proceeding or cause of action, including any settlement

*_______* Indicates that material has been omitted and confidential treatment
 has been requested therefor. All such omitted material has been filed
 separately with the Secretary of Commission in the Company's Application
 Requesting Confidential Treatment pursuant to Rule 24b-2 under the Securities
 Exchange Act of 1934, as amended.

                                                                              16
<PAGE>   17

or other disposition thereof, for which either SB or IDEC seek indemnification
under this Section.

        11.5 IDEC shall defend, indemnify and hold harmless SB and its officers,
directors, shareholders, employees, successors and assigns from and against any
and all damages, claims, costs, losses, liabilities or expenses (including
reasonable attorneys' fees) arising out of, or resulting from or in connection
with IDEC's activities under this AGREEMENT or the Original Agreement except
such damages, claims, costs, losses, liabilities or expenses which are directly
and proximately caused by SB's negligent or wrongful actions. SB shall have the
right to participate in the defense of any such claim, complaint, suit,
proceeding or cause of action referred to in this Section utilizing attorneys of
its choice; provided, however, that IDEC shall have full authority and control
to handle any such claim, complaint, suit, proceeding or cause of action,
including any settlement or other disposition thereof, for which SB seeks
indemnification under this Section.

        11.6 SB shall defend, indemnify and hold harmless IDEC and its officers,
directors, shareholders, employees, successors and assigns from and against any
and all damages, claims, costs, losses liabilities or expenses (including
reasonable attorneys' fees) arising out of, or resulting from or in connection
with SB's activities under this AGREEMENT or the Original Agreement, except such
damages, claims, costs, losses, liabilities or expenses which are directly and
proximately caused by IDEC's negligent or wrongful actions. IDEC shall have the
right to participate in the defense of any such claim, complaint, suit,
proceeding or cause of action referred to in this Section utilizing attorneys of
its choice; provided, however, that SB shall have full authority and control to
handle any such claim, complaint, suit, proceeding or cause of action, including
any settlement or other disposition thereof, for which IDEC seeks
indemnification under this Section.

12.     FORCE MAJEURE

        12.1 If the performance of any part of this AGREEMENT by either party,
or of any obligation under this AGREEMENT, is prevented, restricted, interfered
with or delayed by reason of any cause beyond the reasonable control of the
party liable to perform, unless conclusive evidence to the contrary is provided,
the party so affected shall, upon giving written notice to the other party, be
excused from such performance to the extent of such prevention, restriction,
interference or delay; provided that the affected party shall use its reasonable
best efforts to avoid or remove such causes of non-performance and shall
continue performance with the utmost dispatch whenever such causes are removed.
When such circumstances arise, the parties shall discuss what, if any,
modification of the terms of this AGREEMENT may be required in order to arrive
at an equitable solution.

                                                                              17
<PAGE>   18

13.     GOVERNING LAW

        13.1 This AGREEMENT shall be deemed to have been made in the state of
California and its form, execution, validity, construction and effect shall be
determined in accordance with the laws of the state of California, U.S.A.

14.     ARBITRATION

        14.1 Any dispute, controversy or claim (except as to any issue relating
to intellectual property owned in whole or in part by SB) arising out of or
relating to this AGREEMENT, or the, breach, termination, or invalidity thereof,
shall be settled by arbitration in accordance with the Commercial Arbitration
Rules of the American Arbitration Association, except as modified by this
Section 14. The number of arbitrators shall be three (3). The arbitration
decision shall be binding and not be appealable to any court in any
jurisdiction. The prevailing party may enter such decision in any court having
competent jurisdiction. The arbitration proceeding shall be conducted in the
English language in San Diego, California, unless the parties agree in writing
to conduct the arbitration in another location.

15.     SEPARABILITY

        15.1 In the event any portion of this AGREEMENT shall be held illegal,
void or ineffective, the remaining portions hereof shall remain in full force
and effect.

        15.2 If any of the terms or provisions of this AGREEMENT are in conflict
with any applicable statute or rule of law, then such terms or provisions shall
be deemed inoperative to the extent that they may conflict therewith and shall
be deemed to be modified to conform with such statute or rule of law.

        15.3 In the event that the terms and conditions of this AGREEMENT are
materially altered as a result of Sections 15.1 or 15.2, the parties will
renegotiate the terms and conditions of this AGREEMENT to resolve any
inequities.

16.     ENTIRE AGREEMENT

        16.1 This AGREEMENT, entered into as of the EFFECTIVE DATE, constitutes
the entire AGREEMENT between the parties relating to the subject matter hereof
and supersedes all previous writings and understandings. No terms or provisions
of this AGREEMENT shall be varied or modified by any prior or subsequent
statement, conduct or act of either of the parties, except that the parties may
amend this AGREEMENT by written instruments specifically referring to and
executed in the same manner as this AGREEMENT.

17.     NOTICES

        17.1 Any notice required or permitted under this AGREEMENT shall be sent
by certified mail or overnight courier service, postage pre-paid to the
following addresses of the parties:

                                                                              18
<PAGE>   19

               IDEC PHARMACEUTICALS CORPORATION
               3020 Callan Road
               San Diego, California 92121 U.S.A.
               Attention: Corporate Secretary

               SMITHKLINE BEECHAM p.l.c.
               New Horizons Court
               Brentford, Middlesex TW8 9EP, England
               Attention: Senior Vice President, Worldwide Business Development

               Copy to:

               SMITHKLINE BEECHAM CORPORATION
               Corporate Legal Department
               One Franklin Plaza
               200 North 16th Street
               FP 2225
               Philadelphia, PA  19102
               Attention:  General Counsel - U.S.

        17.2 Any notice required or permitted to be given concerning this
AGREEMENT be effective upon receipt by the party to whom it is addressed.

18.     RECORDATION

        18.1 IDEC shall have the right, at any time during the term of this
AGREEMENT, to record, register, or otherwise notify this AGREEMENT in any patent
office or other appropriate facility anywhere in the world, and SB shall provide
reasonable assistance to IDEC in effecting such recording.

19.     ASSIGNMENT

        19.1 This AGREEMENT and the licenses herein granted shall be binding
upon and inure to the benefit of the successors in interest of the respective
parties. Neither this AGREEMENT nor any interest hereunder shall be assignable
by either party without the written consent of the other; provided, however,
that either party may assign this AGREEMENT or any patent owned by it to any
AFFILIATE or to any corporation with which it may merge or consolidate, or to
which it may transfer all or substantially all of its assets to which this
AGREEMENT relates, without obtaining the consent of the other party.

20.     EXECUTION IN COUNTERPARTS

        20.1 This AGREEMENT may be executed in any number of counterparts, each
of which shall be deemed an original, but all of which together shall constitute
one and the same instrument.

                                                                              19
<PAGE>   20

        IN WITNESS WHEREOF, the parties, through their authorized officers, have
executed this AGREEMENT as of the date first written above.

SMITHKLINE BEECHAM P.L.C.

By:_________________________________
Name:_______________________________
Title:______________________________

IDEC PHARMACEUTICALS CORPORATION

By:_________________________________
Name:_______________________________
Title:______________________________

                                                                              20
<PAGE>   21

                   AMENDED AND RESTATED COLLABORATIVE RESEARCH
                              AND LICENSE AGREEMENT

           IDEC PHARMACEUTICALS CORPORATION--SMITHKLINE BEECHAM P.L.C.

                                   APPENDIX A

                                        *

                                        *

*_______* Indicates that material has been omitted and confidential treatment
 has been requested therefor. All such omitted material has been filed
 separately with the Secretary of Commission in the Company's Application
 Requesting Confidential Treatment pursuant to Rule 24b-2 under the Securities
 Exchange Act of 1934, as amended.

                                                                              21
<PAGE>   22

                   AMENDED AND RESTATED COLLABORATIVE RESEARCH
                              AND LICENSE AGREEMENT

           IDEC PHARMACEUTICALS CORPORATION--SMITHKLINE BEECHAM P.L.C.

                                    EXHIBIT I

                                        *

                                        *

*_______* Indicates that material has been omitted and confidential treatment
 has been requested therefor. All such omitted material has been filed
 separately with the Secretary of Commission in the Company's Application
 Requesting Confidential Treatment pursuant to Rule 24b-2 under the Securities
 Exchange Act of 1934, as amended.

                                                                              22
<PAGE>   23

                   AMENDED AND RESTATED COLLABORATIVE RESEARCH
                              AND LICENSE AGREEMENT

           IDEC PHARMACEUTICALS CORPORATION--SMITHKLINE BEECHAM P.L.C.

                                   EXHIBIT II

                                        *

                                        *

*_______* Indicates that material has been omitted and confidential treatment
 has been requested therefor. All such omitted material has been filed
 separately with the Secretary of Commission in the Company's Application
 Requesting Confidential Treatment pursuant to Rule 24b-2 under the Securities
 Exchange Act of 1934, as amended.

                                                                              23

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00005-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00005-of-00352.parquet"}]]